

CURRICULUM VITAE

A. Name: Daniel Joshua Drucker

B. CV Sept 8 2025

C. Biographical Information

Date of Birth: June 23 1956

Place of Birth: Montreal, Quebec

Education: 1974-1976 Undergraduate Science, University of Ottawa
1980 M.D. University of Toronto, Ontario

Address: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, 600 University Ave Mailbox39
Toronto, Ontario M5G 1X5

Citation metrics <http://scholar.google.ca/citations?user=xmFOoRYAAAAJ&hl=en>

Postdoctoral Training

Internships and Residencies:

1980-1981 Intern in Medicine, Johns Hopkins Hospital, Baltimore
1981-1982 Resident in Medicine, Toronto General Hospital,
1982-1983 Fellow in Endocrinology, Toronto General Hospital
1983-1984 Chief Medical Resident, Toronto General Hospital

Research Fellowships:

1984-1987 Centennial Fellow, Medical Research Council of Canada
1984-1987 Research Fellow in Medicine, Massachusetts General Hospital, Harvard University, Boston

Licensure and Specialty Certification

1980 LMCC examinations
1980 National Board of Medical Examiners Licensing examination
1984 Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC)
1984 Diplomate of the American Board of Internal Medicine
1981 Ontario College of Physicians General License

Hospital Appointments

1980-1981 Fellow in Medicine, Johns Hopkins Hospital
1984-1987 Research Fellow in Medicine, Massachusetts General Hospital
1987-21 Staff Physician, Toronto General Hospital
1991-92 Deputy Director, Mount Sinai/Toronto Hospital Division of Endocrinology
1991- 2025 Cross Appointment Mount Sinai Hospital Associate Staff
2026- Emeritus Staff, Mt. Sinai Hospital
2006- Senior Scientist, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital

Academic and University Appointments

1987- Assistant Professor of Medicine, University of Toronto
 1989- Assistant Professor of Clinical Biochemistry
 1989-91 Assistant Professor of Medical Genetics
 1991-6 Associate Professor of Medicine, Clinical Biochemistry, and Genetics, University of Toronto
 1992-01 Director, Division of Endocrinology, Department of Medicine, University of Toronto
 1996- Professor, Departments of Medicine, University of Toronto
 1997- Professor, Department of Laboratory Medicine and Pathobiology
 2000-11 Director, Banting and Best Diabetes Centre, University of Toronto
 2023- University Professor, University of Toronto

Awards & Honors

1975-1976 University of Ottawa Faculty Merit Scholarship
 1976-1977 Walter F Watkins Scholarship Bradshaw Errington Bursary
 1977-1979 Crocker Foundation Bursary, Walter F Watkins Scholarship
 1979 Elected to membership, Alpha Omega Alpha Medical Society
 1980 Dr. Mitchell F. Kohan Scholarship for special excellence in Internal Medicine, University of Toronto
 1980 Irving Heward Cameron Gold Medal in Surgery, University of Toronto
 1981-1982 Second Prize, Toronto General Hospital Research Competition
 1983-1984 First Prize, Toronto General Hospital Research Competition
 1984 Student Award for Research, Canadian Society for Clinical Investigation
 1984-1987 Centennial Fellow, Medical Research Council of Canada
 1986 American Federation for Clinical Research-Outstanding Trainee Award
 1987- 89 Research Scholar of the Medical Research Council of Canada
 1989-94 Ontario Ministry of Health Career Scientist Award
 1989 Elected Fellow of the American College of Physicians
 1989-94 Appointed Reuben and Helen Dennis Research Scholar in Diabetes Research, Toronto General Hospital
 1990 University of Toronto Department of Medicine Research Award
 1993 Alan Bruce Robertson Young Investigator Award of the Clinical Research Society of Toronto
 1993 Richard E. Weitzman Award of the Endocrine Society for Scientific Achievement by a young investigator
 1994-99 MRC Scientist Award
 1995 Elected Member, American Society for Clinical Investigation
 1996 Canadian Diabetes Association Outstanding Young Scientist Award
 1996 William Goldie Prize for academic contributions to Internal Medicine, University of Toronto
 1998 Viktor Mutt Award from the International Society for Study of Regulatory Peptides
 1999-2004 MRC Senior Scientist Award
 2002 Canadian Society for Clinical Investigation Distinguished Scientist Award
 2004 Bristol Myers Squibb Freedom to Discover Award for Metabolic Research
 2004 Canada Research Chair in Regulatory Peptides
 2005 University Health Network Inventor of the Year Award
 2006 Elected to membership in the Association of American Physicians (AAP)
 2008 Prix Galien Canada award for outstanding pharmaceutical research
 2009 The Endocrine Society Clinical Investigator Laureate Award
 2010 Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology
 2012 The Claude Bernard Medal & Lecture, European Association for the Study of Diabetes
 2012 CIHR CMAJ Top Achievements in Health Research Award
 2012 Elected Fellow of the Royal Society of Canada
 2012 Lloyd S.D. Fogler Award for research excellence, Mt. Sinai Hospital
 2013 Oon International Award for Preventive Medicine, Cambridge University School of Medicine, United Kingdom
 2014 Banting Medal for Scientific Achievement, American Diabetes Association
 2014 Manpei Suzuki International Prize for Diabetes Research, Manpei Suzuki Foundation, Tokyo, Japan
 2015 Rachmiel Levine Award for Scientific Achievement in Diabetes Research, City of Hope, California
 2015 Institute of Medical Sciences Graduate Course Lecturer Award, University of Toronto

2015 Elected Fellow of the Royal Society of London, UK
 2015 Appointed Officer of the Order of Canada
 2017 Rolf Luft Award in Endocrinology and Diabetes Research, Karolinska Institute
 2017 The Harrington Prize for Innovation in Medicine, ASCI and the Harrington Institute
 2018 The Canadian Organization for Rare Disorders Scientific Leadership Award
 2018 The Manning Foundation Principal Innovation Award
 2019 The Harrison Medal, Australian Endocrine Society
 2019 The Harold Hamm International Prize for Diabetes Research
 2019 The Novo Nordisk Foundation EASD Prize for Excellence in Diabetes Research
 2019 The Helmholtz Diabetes Centre Lifetime Achievement Award
 2020 The Endocrine Society John Baxter Award for Entrepreneurship
 2020 The Transatlantic Medal of the British Endocrine Society
 2020 The Warren Alpert Foundation Harvard Medical School Prize for Biomedical Research
 2021 Canada Gairdner International Award for Biomedical Science
 2021 Elected to the National Academy of Sciences, USA
 2022 Inducted into the Canadian Medical Hall of Fame
 2023 The Wolf Prize in Medicine
 2023 Elected to the National Academy of Medicine (USA)
 2023 The VinFuture Prize for innovators with outstanding achievements in emerging fields
 2024 The Princess Asturias Award for Technical and Scientific Research
 2024 The TOPS Research Achievement Award, The Obesity Society
 2025 The BBVA Frontiers of Knowledge Award in Biology and Biomedicine
 2025 AACR-Irving Weinstein Foundation Distinguished Lectureship Award, American Association for Cancer Research
 2025 American Physiology Society- The Solomon A. Berson Distinguished Lectureship Award
 2025 The 2025 Warren Triennial Prize, Massachusetts General Hospital
 2025 The Breakthrough Prize in Life Sciences and Medicine
 2025 American Association of Clinical Endocrinology Kahn-Tan-Faiman Frontiers in Science and Endocrinology Award
 2025 Honorary Master of the American Association of Clinical Endocrinology (MACE) Distinction
 2025 The BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine
 2025 The Fred Conrad Koch Lifetime Achievement Award, The Endocrine Society

Public recognition

2024 Time 100 most influential people
 2024 Time 100 most influential people in health care
 2024 American Academy of Achievement, Golden Plate Award

Named Lectureships

1999 Clinical Research Society of Toronto Novartis Senior Scientist Award
 1999 Clinical Research Institute, University of Montreal Pfizer Visiting Professor
 1999 Annual Peter Laurie Lecture of the Juvenile Diabetes Foundation
 2001 University of Utah, Salt Lake City: Tyler Memorial Lecture
 2002 The Kroc Lectureship in Diabetes at the University of Alabama, Birmingham
 2005 The Annual Williams Lecture in Diabetes, University of Rochester
 2005 The Annual Melvin C. Gluck Lectureship, New York University School of Medicine
 2005 Annual Novo Nordisk Lecturer in Diabetes, McGill University
 2006 The 9th Annual John Ensink Lecture, University of Washington, Seattle
 2006 The Rufus Cole Memorial Lecture, Rockefeller University, New York
 2007 Charles Hollenberg Award Lecture, University of Toronto
 2007 Charles H Best Lecture Award, Toronto Diabetes Association
 2007 The Catherine Tuck Memorial Lecture, Columbia University
 2007 Donald F. Steiner Award for Outstanding Diabetes Research, University of Chicago
 2009 The Albert and Miriam Weinstein Lectureship, Vanderbilt University

2009 Beth Zaruby Memorial Lecture in Diabetes Research, University of Calgary Faculty of Medicine
 2009 Pfizer Visiting Professor Lectureship, University of Pennsylvania
 2009 29th Novo Nordisk Plenary Lecture of the Irish Endocrine Society
 2009 CH Best Lectureship and Award, Department of Physiology, University of Toronto
 2011 Priscilla White Lectureship in Diabetes and Metabolism, Harvard Medical School
 2011 AACE Visiting Professor, Beth Israel Hospital, Harvard Medical School
 2012 Harold Rifkin Lectureship, Albert Einstein College of Medicine, Yeshiva University New York
 2014 Lydia J. Robert lectureship in Molecular Metabolism and Nutrition, University of Chicago
 2014 D. Walter Cohen DDS Lectureship in Diabetes, Drexel University, Philadelphia
 2014 Dr. J. David Grimes Lecture Ottawa Hospital Research Institute, University of Ottawa
 2015 McGill Novo Nordisk Lectureship in Diabetes, Montreal, Canada
 2015 Tisdale Lectureship, University of Vermont
 2015 The Bill Vlahos Memorial Lecture, University of British Columbia
 2015 University of Utah, Salt Lake City: Frank H Tyler M.D. Memorial Lecture
 2015 Jacques Genest Lectureship Award, Canadian Society of Endocrinology & Metabolism
 2016 Richard Horton Lecture in Endocrinology, University of Southern California School of Medicine
 2016 3d Annual George Cahill Jr. Lectureship, University of Montreal Diabetes Research Centre
 2016 The Myron B Zinn Memorial Lecture, Maimonides Society, San Antonio, Texas
 2017 The Oliver Smithies Lecture, University of Toronto, Canada
 2018 The Piero P. Foa Memorial lectureship Wayne State University, Detroit
 2018 The 11th Levi J. Hammond Lecture, University of Pennsylvania Perelman School of Medicine
 2018 The 8th Robert D. Utiger Memorial Lecture in Endocrinology, Brigham and Women's Hospital, Harvard University
 2018 The Annual Kroc Lectureship, Ohio State University, Wexner Medical Center
 2018 The 2018 Düsseldorf Diabetes Lecture, German Diabetes Centre
 2019 I.G. Bromberg Memorial Visiting Professorship, UT Southwestern, Dallas
 2019 7th Annual Wylie Vale Memorial Lectureship, Salk Institute, San Diego
 2019 The Harrison Medal Award Lecture Australian Endocrine Society
 2019 Kroc Visiting Scholar Lecture, University of Washington, Seattle WA
 2019 The Helmholtz Diabetes Lecture, Munich Germany
 2019 The Fitkin Oration, Australian Society for Medical Research
 2019 The Max McKenzie Lectureship, University of Miami
 2020 The Annual Distinguished Speaker Lectureship in Endocrinology, University of California, Irvine
 2020 The Josiah Brown Lectureship, University of California, Los Angeles
 2020 DREAM Trainee Lectureship in Diabetes, University of Manitoba
 2021 The Stanley Mirsky, MD lectureship, Icahn School of Medicine, Mount Sinai Hospital, NY
 2021 The Albert Renold Lecture, the Swiss Endocrine Society, Switzerland
 2022 The Tinsley Randolph Harrison Society visiting professorship lecture, Vanderbilt University
 2022 The John Service Memorial Lecture, Mayo Clinic
 2022 The George L Blackburn Lecture, Dartmouth Geisel School of Medicine
 2022 The Jackson Memorial Lecture, South African Endocrinology, Metabolism, and Diabetes Society, Cape Town
 2023 The Ray A and Robert L Kroc Lecture, Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania
 2023 The Kendall-Hench Lecture, Mayo Clinic, Rochester Minnesota
 2023 The Bernard Langer Lecture in Health Sciences, Institute of Medical Sciences, University of Toronto
 2023 The Brosnan Lecture in Biochemistry, Memorial University
 2023 The John Morgan lectureship, University of Pennsylvania
 2024 The Veda R. and Buford L. Nichols Jr. Lecture, Baylor College of Medicine, Houston
 2024 The John P. Peters Lecture, Yale University, Department of Medicine, New Haven
 2024 The Bobby R Alford Distinguished Lectureship, Baylor College of Medicine, Houston
 2024 The Lewis Landsberg Obesity Lectureship, Northwestern Feinberg School of Medicine, Chicago
 2024 The Jeffrey S. Flier and Eleftheria Maratos-Flier Lectureship, BIDMC, Harvard, Boston
 2024 The Blackburn Keynote Lecture, The Blackburn Course in Obesity Medicine, Harvard University
 2024 The Morris Kates lectureship, Department of Biochemistry, University of Ottawa
 2024 The Wilkins Visiting Professorship & Lecture, Boston University Medical Center
 2024 Inaugural Eating Disorders Lecture at Rutgers Addiction Research Center, Rutgers University

2024 The Lemieux Lecture in Biotechnology, University of Alberta
 2024 The Grant R Wilkinson Distinguished Lectureship in Clinical Pharmacology, Vanderbilt University
 2024 The Irwin Eskin MD Lecture in Biomedical Science, Vanderbilt University
 2024 The Phil Wells Lectureship, University of Ottawa
 2024 The Mary Shorb Lecture, University of Maryland
 2025 The DeWitt Goodman Lecture, Columbia University School of Medicine
 2025 The John F. Crigler, Jr., M.D. Memorial Lecture, Boston Childrens Hospital, Harvard
 2025 The Lee E. Farr Lecture, Yale University School of Medicine
 2025 The Richard Horton Lectureship, USC School of Medicine
 2025 The Chicago Scholars Lectureship, University of Chicago & Northwestern University
 2025 The Inaugural Dr. David CW Lau Lectureship, Canadian Association of Bariatric Physicians and Surgeons

Academic Activities

1987- Reviewer for *Endocrinology*, *Annals of Internal Medicine*, *Molecular and Cellular Biology*, *Molecular Endocrinology*, *Endocrinology*, *Journal of Clinical Endocrinology and Metabolism*, *Journal of Biological Chemistry*, *Journal of Clinical Investigation*
 1988- Grant reviewer for Manitoba Foundation for Health Sciences, HSC Research Foundation MRC, NCI, CDA, and Kidney Foundation
 1988-92 Appointed to NCI Grants panel D, Molecular Biology
 1989-92 Appointed to Canadian Diabetes Association Grants Panel-Personnel Awards
 1990-92 Appointed Chairman, Molecular and Cellular Biology Grants panel D, National Cancer Institute
 1990-4 Appointed to Medical Sciences Advisory Board, Juvenile Diabetes Foundation International
 1991-4 Appointed to University of Toronto Connaught Life Sciences Review Panel
 1992-94 JDF Canada Government and Research Committee
 1994 Postgraduate Endocrine Assembly Program Committee Toronto November
 1995-6 Appointed to Research Grants Panel, Canadian Diabetes Association
 1994/5 Vice-President, Clinical Research Society of Toronto
 1996 President, Clinical Research Society of Toronto
 1997-00 Appointed Chair, MRC Endocrinology Grants panel
 1998 Ontario Research and Development Challenge Fund Scientific Review Panel
 1999-00 Ad Hoc Member, NIH Metabolism Study Section
 1999-02 JDRF Medical Science Review Committee
 1999- Endocrine Society Meetings and Educational Programs Committee
 1999-01 Endocrine Society Annual Meeting Steering Committee
 1999 Chair, IUPHAR Glucagon and Related Receptors Subcommittee
 2000 Endocrine Society Media Relations Committee
 2000-2 Appointed to Editorial Board, *Endocrinology*
 2001 Endocrine Society E-Learning Subcommittee
 2001 Appointed to Editorial Board, *American Journal of Physiology-Endocrinology and Metabolism*
 2001-4 Appointed to Editorial Board, *Diabetes*
 2002 Appointed to Editorial Board, *Molecular Endocrinology*
 2002 Meeting Organizer and Chair, Genomics and Proteomics Course for the Endocrine Society, New Orleans Nov 17-18, 2003
 2002-4 Gairdner Foundation Awards Committee
 2002 Steering Committee of International Symposia on Regulatory Peptides
 2002-8 Editor, *Endocrinology*
 2002 Organized and chaired 2002 Endocrine Society Hot Topics Meetings on “Genomics and Proteomics in Endocrine Systems, New Orleans, November 15-16, 2002
 2003-6 Elected to Council, Endocrine Society
 2003 Organizing and Program Committee, ADA 2003 Meeting on Novel Roles of GI Hormones in Energy Homeostasis, Long Beach, CA Dec 9-12, 2003
 2003 American Diabetes Association Program Committee
 2005- Editorial Board, *Nature Reviews Endocrinology and Metabolism*

2006-15 Editorial Board, Endocrine Reviews
 2008-11 Editorial board, Gastroenterology
 2009 Chair, CQDM-FRSQ Grants Panel on FRSQ-Pharmaceutical Research
 2008-11 Awards Committee, Canadian Society of Endocrinology and Metabolism
 2010-4 Awards Committee, Endocrine Society
 2011-2 Chair, Awards Committee, Endocrine Society
 2011 CIHR NCIC Team Grant Cancer Review Panel
 2011-15 Scientific Advisory Board Norcomm2 Mouse Genetics Consortium
 2012-4 Editorial Board, Endocrinology
 2012-5 Scientific Advisory Board, The Novo Nordisk Foundation Center for Basic Metabolic Research University of Copenhagen
 2013-14 Scientific Advisory Board, Institute for Translational Medicine and therapeutics, University of Pennsylvania
 2013-4 TrialNet Incretin Therapy for Prevention of Type 1 Diabetes Protocol Committee
 2014- Consulting Editor, Diabetes
 2014-20 International scientific review panel, Leducq Foundation, Paris
 2014-7 Nominating Committee, Endocrine Society
 2016-18 EASD Claude Bernard Award Selection Committee
 2016-17 Manpei Suzuki Award Committee
 2016- Editorial Board, Journal of the Endocrine Society
 2016-19 Royal Society, London, Sectional Committee 10 Evaluation of candidates for election to fellowship
 2017- American Diabetes Association Pathway to Stop Diabetes Mentor Advisory Panel
 2018- Editorial Board, Molecular Metabolism
 2018-21 Editor-in-Chief, Endocrine Reviews
 2018-21 Chair, American Diabetes Association's Medicine, Science and Health Care Awards Committee
 2019-21 External Advisory Board Review, Lady Davis Research Institute, Montreal
 2020- Rolf Luft Lectureship and Prize Awards Committee, Karolinska Institute
 2020-3 External Advisory Board, University of Pennsylvania Institute for Diabetes, Obesity and Metabolism
 2021- Editorial Board, Cell Metabolism
 2022- Advisory Board, McMaster Centre for Metabolism, Obesity and Diabetes Research
 2021-3 Chair, Pfizer ASPIRE Obesity Grants Panel
 2022- Chair EASD Novo Nordisk Foundation Prize Committee for Excellence in Diabetes
 2024 Selection Committee Editorial Board, JCI Insight, ASCI
 2024- Gairdner Foundation, Medical Advisory Board
 2025- Breakthrough Prize Award Committee

University of Toronto Committees and Academic Responsibilities

Banting and Best Diabetes Centre Research and Development Committee (1988-91)
 Banting and Best Diabetes Centre Facilities Committee (1987-89)
 Banting and Best Diabetes Center Executive Committee (1991-ongoing)
 Toronto Diabetes Association Executive (1989-91)
 Coordinator, TDA Research competition (1989-91)
 Department of Medicine Economics Committee (1988-94)
 University of Toronto Endocrinology Executive (1989-2001)
 Chair, Connaught Life Sciences Panel, University of Toronto (1993-4)
 Coordinator, City-wide Endocrine rounds, University of Toronto (1989-92)
 Department of Medicine Research Committee, University of Toronto (1990-92)
 Strategic Planning Committee, University Division of Endocrinology (1990-92)
 Clinical Research Society of Toronto Executive Committee (1993-95)
 Banting and Best Diabetes Centre/Eli Lilly Diabetes Research Program Executive Committee (1996-00)
 Toronto General Hospital Research Reorganization Committee (1998-99)
 UHN-Mt. Sinai Economics Committee (2001-4)
 Promotions Committee, University of Toronto Faculty of Medicine (2004)

Member, Dean's Taskforce on Industry Relationships and Commercialization (2009-11)
Member, Faculty of Medicine Innovation/Entrepreneurship Committee (2014-16)
Department of Medicine Research Committee (2014-)
Department of Medicine Merit Review Committee (2016-)
Chair, Program Committee, for April 2021 100th Anniversary of the Discovery of Insulin Meeting

Peer-reviewed Grant Support: 1987-ongoing

1)Deans Fund 1987

Glucagon gene expression \$5,000.00

2)Connaught Foundation 1987

Molecular Biology of Glucagon Gene Expression \$13,650.00

3)Bickell Foundation 1987

Hormone Gene Expression \$10,000.00

4)Cummings Foundation 1987

Glucagon Gene Transcription (US Funds) \$24,371.00

5)Medical Research Council Operating 1987-1990

Glucagon gene expression \$127,400.00

6)National Cancer Institute Operating 1987-1990

Hormone gene expression in neoplastic cells \$146,783.00

7)Medical Research Council Operating 1990-1993

Glucagon gene expression \$261,900.00

8)National Cancer Institute Operating 1990-1993

Hormone gene expression in neoplastic cells \$250,000.00

9)Canadian Diabetes Association Operating 1990-1991

Parathyroid hormone-like peptide in the pancreas \$120,000.00

10)Canadian Diabetes Association Operating 1992-1993

Molecular Determinants of Islet Cell Differentiation \$50,000.00

11)Dennis Scholarship 1990-1993

Diabetes Research, Banting and Best Diabetes Centre \$30,000.00

12)Juvenile Diabetes Foundation International 1992-94

LIM domain proteins in the islets of Langerhans (US) \$100,000.00

13)National Cancer Institute Operating 1993-1996

Cheryl F. Rosen and Daniel J. Drucker Co investigators

Effects of ultraviolet radiation on mammalian keratinocytes \$224,082.00

14)Medical Research Council of Canada Operating 1993-1998

Regulation of glucagon gene expression Now 90,000 per annum \$476,500.00

15)National Cancer Institute Operating 1993-1994

Regulation of parathyroid hormone related peptide gene expression \$39,291.00

- 16) National Science and Engineering Research Council of Canada *Identification and efficacy analysis of a novel small bowel growth factor* 1993-95 \$235,000.00
- 17) Juvenile Diabetes Foundation International Operating 1994-96
Development and analysis of a mouse model with a null mutation at the GLP-1 receptor locus \$130,000.00
- 18) Canadian Diabetes Association Operating 1995-96
Molecular Characterization of a novel GLP-1 related peptide \$58,385.00
- 19) NSERC-Industry Collaborative R & D Award 1996-98
Characterization and pharmacological development of a novel intestinal growth factor \$451,580.00
- 20) National Cancer Institute 1996-99
C. Rosen and D. Drucker co-PI
Cellular Perturbations in response to UVB radiation \$331,186.00
- 21) Juvenile Diabetes Foundation International Operating 1996-98
Characterization of mice with a germline disruption of the GLP-1 receptor gene \$100,000.00
- 22) Canadian Diabetes Association Operating 1998-2000
D. Drucker P.I.
Role of GIP, GLP-1 and leptin in glucose homeostasis
\$59,000/annum
- 23) Juvenile Diabetes Foundation International 1998-2000
D. Drucker P.I.
Central and peripheral determinants of GLP-1 action
\$96,500/annum US
- 24) Medical Research Council of Canada Operating 1998-2001
D. Drucker
The role of GLP-2 in the control of intestinal growth
\$64,755/annum
- 25) Medical Research Council of Canada Operating 1998-2003
D. Drucker
Glucagon Gene Expression
\$139,070/annum
- 26) Eli Lilly-BBDC University of Toronto Research Program 1998-2000
D. Irwin and D. Drucker coPI
In vitro and in vivo models for regulation of the human proglucagon gene
\$60,000/annum
- 27) ORDCF Research Program 1999-2002
D. Drucker PI
Novel glucagon-like peptide agonists and antagonists
\$175,000/annum from each partner
- 28) Canadian Diabetes Association
D. Drucker PI
Peptide hormones and regulation of glucose homeostasis
July 1 2000-2002
\$60,000 per annum

29) Canadian Diabetes Association
C. Rosen PI D. Drucker coPI
Metabolic characterization of a novel AMPK-related protein kinase
July 1 2000-2001
\$60,000 per annum

30) Juvenile Diabetes Foundation International
D. Drucker PI
GLP-1 receptor and the control of glucose homeostasis
Sept 1 2000-Sept 1 2003
\$185,810 US per annum

31) CIHR
D. Drucker PI
Physiological significance of GLP-2 action 14799
April 1 2001-2006
\$166,782/annum

32) National Institutes of Health R01 DK59751-01
J. Elmquist PI D. Drucker Co-PI-Subcontract for Canadian PI
The role of central GLP-1 systems in counter-regulatory responses
Feb 1 2001-2003
\$320,074 US/annum

33) National Cancer Institute of Canada
PI: D. Drucker
Title: GLP-2 receptor and the control of neoplastic cell growth
Award term-3 years, July 1 2001-2004
Amount Awarded: \$126,467/annum

34) Canadian Diabetes Association Grant 1212
PI: D. Drucker
Title: Incretin receptors and the control of glucose homeostasis
Award Term: 3 years, July 1 2002-5
Amount Awarded" \$67,500/annum

35) CIHR
PI: Dr. P. Brubaker co-PI Dr. D. Drucker
Role of gastrointestinal peptides in vagally-mediated satiety signaling
Pilot Project /grant
Award Term 1/11/2002-10/2003
Amount Awarded: \$47,200

36) Ontario Research and Development Challenge Fund
PI: D. Drucker
Program in Gastrointestinal Genomics
Award Term 1/1/2003 to 12/31/2005
Amount Awarded \$756,367 pa

37) CIHR 117237
PI: Dr. D. Drucker
Glucagon Gene Expression and Glucagon Action
Award Term 1/10/2003-30/9/2008

Amount Awarded: \$162,408 pa

38) JDRF

PI: Dr. D. Drucker

GLP-1 receptor signaling, islet cell growth and survival

Award Term 1/10/2003-30/9/2006

Amount awarded \$165,000 USD pa

39) Bristol Myers Squibb Foundation

Freedom to Discover Unrestricted Research Grant

Metabolic Disease Research

January 1 2004-Dec 31 2008

\$100,000 USD per annum

40) NIH R21 DK06636-01

GLP-1 to enhance islet transplantation

PI: Dr. A. Powers, Vanderbilt University

Subcontract: D. Drucker

9/30/03-9/30/05

Amount of subcontract: \$68,040 USD

41) Canadian Diabetes Association GA-3-05-1847-DD

GIP and the islet β cell

PI: Dr. D. Drucker

7/1/2005-6/30/2007

\$75,000 CAD/annum

42) Heart & Stroke Foundation of Ontario NA 5926

Role of glucagon-like peptides in cardiac health and disease

PIs: Mansoor Husain and Daniel J. Drucker

7/1/2006-6/30/2009

\$94,000/annum

43) National Cancer Institute of Canada

GLP-2 receptor activation and the control of cell growth

PI: Daniel J. Drucker

7/1/2006-6/30/2011

\$141,000/annum

44) CIHR

Physiology of GLP-2 Action

PI: Daniel J. Drucker

4/1/2006-3/30/2011

\$135,368/annum

45) CIHR-Industry Operating Grant

Cardiovascular biology of incretin enhancers

PI: Daniel J. Drucker

09/01/2006-08/30/2009

\$162,000/annum

46) Juvenile Diabetes Research Foundation

Enhancing incretin action for the treatment of diabetes

PI: Daniel J. Drucker

10/01/2006-9/30/2009
\$165,000 USD/annum

47) Canadian Institutes for Health Research
Elucidating the role of GIP in glucose homeostasis
PI: Daniel J. Drucker
4/1/2007-3/31/2012
\$111,393/annum

48) CIHR
Role of Gut hormones and DPP-4 in bone and mineral homeostasis
PI: Dr. D. Drucker Co-PI Dr. M. Grynepas
Dates of Approved Project 1/1/2008-31/3/2008
Direct Costs Awarded: \$100,000 Partial funding for “non-funded CIHR grant application
Percent Effort Allocation: 5 %

49) Canadian Diabetes Association
Incretin hormones, diabetes and skeletal health
PI: Dr. D. Drucker Co-PI Dr. M. Grynepas
Dates of Approved Project 7/1/2008-6/30/2011
Direct Costs Awarded: \$270,750 over 3 years

50) CIHR MOP 93749
Elucidation of novel mechanisms of glucagon action
PI: Dr. D. Drucker
Dates of Approval: 1/4/2009-31/3/2014
Direct costs Awarded: \$147,586 per annum

51) HSFO T6757
The role of glucagon-like peptide-1 in cardiac health and disease
PI: Dr. M. Husain co-PI Dr. D. J. Drucker
Dates of Approval: July 1 2009-June 30 2014
Direct costs: \$724,281 over 5 years
Percent Effort 5%

52) HSFO NA 6997
Incretin action and the cardiovascular system
PI: Dr. D. Drucker co-PI Dr. M. Husain
Dates of Approval July 1 2010-June 30 2013
Direct Costs: \$109,100 per annum
Percent Effort: 10%

53) Canadian Diabetes Association OG-3-11-3270-DD
GPR119 and the control of glucose homeostasis
PI: Daniel J Drucker
Dates of Approval: July 1 2011-June 30 2014
Direct costs: \$91,667/annum
Percent Effort:10%

54) CIHR DC0190GP
Gipr and the control of glucose homeostasis
PI: Daniel J Drucker
Dates of Approval: April 1 2012-March 31 2017
Direct costs: \$156,423

Percent Effort: 10%

55) CIHR 14799

Enteroendocrine control of nutrient assimilation

PI: Dr. Daniel J Drucker

Date of approval Oct 1 2012-Sept 30 2017

Direct costs: 161,925

Percent effort: 15%

56) HSFC GIA G-14-0005953 1417

Cardiovascular biology of dipeptidyl peptidase 4

Date of Approval: July 1 2014-June 30 2017

Direct costs \$82,080 per annum

Percent effort 10%

57) CIHR 136942

Glucagon receptor and the control of metabolism

PI: Dr. Daniel J Drucker

Date of approval Oct 1 2014-Sept 30 2019

Direct costs: 149,873 per annum

Percent effort: 15%

58) CIHR

Molecular and cellular mechanisms of DPP-4 action

PI: Dr. Daniel Drucker

Date of Approval: Oct 1 2015-Sept 30 2018

\$138,518 per annum

Percent effort: 10%

59) CIHR 154321

Mechanisms of peptide hormone action: metabolic and therapeutic implications

PI: Dr. Daniel J. Drucker

Date of Approval: July 1 2017-June 30 2024

\$652,743 annum

Percent effort: 75%

60) Canada Israel Health Research Program CIHR

Immunometabolic roles and therapeutic potential of glucose-dependent insulintropic polypeptide (GIP)

Canadian PI: Dr. Daniel J. Drucker

Date of Approval November 1 2019-Oct 31 2022

Total Direct Costs: \$670,000

Percent Effort 15%

61) JDRF Grant Key: 5-SRA-2020-1058-S-B

Project Title: Using novel transplantation strategies and HLA-edited hypoimmunogenic hPSCs to develop a superior islet-like product for T1D treatment

PI: Dr. C Nostro

12/01/2020 - 11/30/2025

Total Direct Costs \$30,000 per annum to D Drucker

Percent Effort 5%

62) Amgen Inc

Gut Hormone Biology Research Program

PI: Daniel J Drucker

08/15/2023=08/14/2025

Total direct and indirect costs \$1,635,293.80 CAD

Percent effort: 15%

63) CIHR Grant 192044

Project title: Direct and indirect mechanisms of GLP-1 action

PI: Daniel J Drucker

07/1/2024-6/30/2029

Total direct costs: \$998,325

Percent effort 15%

64) Zealand Pharma A/S

Project title: Anti-inflammatory mechanisms of glucagon-like peptides

PI: Daniel J Drucker

03/08/2024-12/31/2026

Direct and Indirect costs: \$560,277.30 USD

Percent effort 10%

65) Eli Lilly Inc

Project title: Incretins in Inflammation

PI: Daniel J Drucker

11/27/2024-11/26/2026

Total direct and indirect costs: \$1,200,000.00 USD

Percent effort 10%

66) Diabetes Canada-Canadian Cancer Society (OG-3- 24-5819-DD)

Project title: "New therapeutic options to prevent diabetes and obesity-associated cancers"

PI: Daniel J Drucker

1/1/2025-31/12/2027

Total Direct costs \$450,000.00

Percent effort 15%

Personnel Awards:

Awarded MRC Scholarship: Held 1987-1989 \$45,000.00/annum

Awarded MRC Career Scientist, 1994-99, \$70,000/year

Awarded CIHR Senior Scientist 1999-2004

Awarded Canada Research Chair in Regulatory Peptides 2004-10 \$200,000 per annum

Awarded BBDC-Novo Nordisk Chair in Incretin Biology May 2010-2025 \$180,000 per annum

Awarded Renewal, Canada Research Chair in Regulatory Peptides 2011-18 \$200,000 per annum

Patents

- 1) *Glucagon-like peptide 2 analogs*. US Patent Issued August 4 1998 No 5,789,379 **D. J. Drucker**, A. Crivici, M. Sumner-Smith
- 2) *Glucagon-like peptide 2 and its therapeutic use*. US Patent Issued Nov 10, 1998 No. 5,834,428 **D. J. Drucker**
- 3) *Method of using exendin and GLP-1 to affect the central nervous system* US Patent Issued Dec 8 1998 No. 5,846,937 **D. J. Drucker**
- 4) *Compositions and methods for enhancing intestinal function*. US Patent Issued 5,952,301 September 14 1999 **D. J. Drucker**
- 5) *Glucagon-like peptide 2 and its therapeutic use*. US Patent Issued Nov 23 1999 No. 5,990,077 **D. J. Drucker**
- 6) *Antagonists of intestinotrophic GLP-2 peptides*. US Patent issued Nov 30 1999 No. 5,994,500 **D. J. Drucker**, A. Crivici, M. Sumner-Smith.
- 7) *Methods of enhancing functioning of the upper gastrointestinal tract* US Patent issued 6,051,557 April 18 2000 **D. J. Drucker**
- 8) *Intestinotrophic Glucagon-like peptide 2 analogs*. US Patent Issued February 6, 2001 No. 6,184,201 **D. J. Drucker**, A. Crivici, M. Sumner-Smith.
- 9) *Methods of enhancing functioning of the large intestine*. US Patent 6,297,214 Issued Oct 2 2001 **D. J. Drucker**
- 10) *Antagonists of intestinotrophic GLP-2 peptides* US Patent 6,489,295 Issued December 3 2002 **D. J. Drucker**, A. E. Crivici, M. Sumner-Smith.
- 11) *Methods of enhancing functioning of the large intestine*. US Patent 6,586,399 Issued July 1 2003 **D. J. Drucker**
- 12) *Polynucleotides encoding proexendin, and methods and uses thereof*. US Patent issued April 20 2004 6,723,530 **D. J. Drucker**
- 13) *Method of regulating glucose metabolism, and reagents related thereto* US Patent issued Oct 12 2004 6,803,357 Co-inventors W. Bachovchin, A.G. Plaut, and **D. J. Drucker**
- 14) *Methods of regulating glucose metabolism and reagents related thereto* W. Bachovchin, A. Plaut and **D. J. Drucker** US Patent 6,890,898 Issued May 10 2005
- 15) *Glucagon-like peptide 2 and its therapeutic use*. **D. J. Drucker** US Patent issued May 23 2006 7,049,284
- 16) *Methods of regulating glucose metabolism and reagents related thereto* W. Bachovchin, A. Plaut and **D. J. Drucker** US Patent 7,078,381 Issued July 18 2006
- 17) *Method of regulating glucose metabolism, and reagents related thereto* W. Bachovchin, A. Plaut and **D. J. Drucker** US Patent 7,157,429 Issued Jan 2 2007
- 18) *Methods of enhancing functioning of the large intestine* **D. J. Drucker** US Patent 7,176,182 Issued February 13 2007
- 19) *Method of regulating glucose metabolism, and reagents related thereto* W. Bachovchin, A. Plaut and **D. J. Drucker** US Patent 7,459,428 Issued December 2 2008

- 20) *Methods of enhancing functioning of the large intestine* **D. J. Drucker** US Patent 7,642,241 Issued January 5 2010
- 21) *Glucagon-like peptide-2 analogs* **D. J. Drucker**, A. Crivici, M. Sumner-Smith US Patent 7,781,401 issued August 24 2010
- 22) *Method of regulating glucose metabolism, and reagents related thereto* W. Bachovchin, A. Plaut and **D. J. Drucker** US Patent 7,829,530 issued November 9 2010
- 23) *Enhancement of GLP-2 activity of suppressing appetite* **D. J. Drucker** and J. A. L. Lovshin, US Patent 7,862,824 issued January 4 2011
- 24) *Glucagon-like peptide-2 and its therapeutic use* **D. J. Drucker** US Patent 7,888,317 Issued February 15 2011
- 25) *Methods of enhancing functioning of the large intestine* **D. J. Drucker** US Patent 7,960,344 issued June 14 2011
- 26) *Methods of enhancing functioning of the large intestine* **D. J. Drucker** US Patent 8,278,273 October 2 2012
- 27) *Method of regulating glucose metabolism, and reagents related thereto* W. Bachovchin, A. Plaut and **D. J. Drucker** US Patent 8,318,669 issued November 27 2012
- 28) *Method of regulating glucose metabolism, and reagents related thereto* W. Bachovchin, A. Plaut and **D. J. Drucker** US Patent 8,513,190 issued August 20 2013
- 29) *Methods of enhancing functioning of the large intestine* **D. J. Drucker** US Patent 8,603,976 issued December 10 2013
- 30) *Glucagon-like peptide-2 analogs* **D. J. Drucker**, A. Crivici, M. Sumner-Smith US Patent 8,846,625 issued September 30 2014
- 31) *Glucagon-like peptide-2 analogs* **D. J. Drucker**, A. Crivici, M. Sumner-Smith US Patent 8,933,039 issued January 13 2015
- 32) *Method of regulating glucose metabolism, and reagents related thereto* W. Bachovchin, A. Plaut and **D. J. Drucker** US Patent 9,044,424 issued June 2 2015
- 33) *Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist* **D. J. Drucker & L. L. Baggio** US Patent 9,168,288 issued October 27 2015.

Filed/Issued Foreign patents not listed

E Peer-reviewed Publications

Original Research

1. **Drucker D. J.** Aortic Aneurysms. University of Toronto Medical Journal 1976 56:112-6 NP
2. Eggo M.C., **Drucker D. J.**, Cheifetz R., Burrow G.N. Post-translational modification of prothyroid hormone. Cdn. J. Biochem Cell Biol 1983 61:662-669
3. **Drucker D. J.**, Zinman B. Pathophysiology of beta cell failure following prolonged remission of insulin dependant diabetes mellitus(1DDM) Diabetes Care 1984 7:83-87
4. **Drucker D. J.**, Shumak S., Angel A. Schmidt's syndrome presenting with intrauterine growth retardation and postpartum addisonian crisis. Am. J. Ob. Gyn.1984 149:229-230
5. **Drucker D. J.**, Eggo M.C., Salit I. E., Burrow G. N. Ethionamide induced goitrous hypothyroidism. Annals Int Med 1984 100:837-839
6. **Drucker D. J.**, Bookman A. Pseudotumor Cerebri with urticaria, hypocomplementemic vasculitis and cryoglobulinemia. Can Med Assoc J. 1985 132:147-149
7. **Drucker D. J.**, Shandling M. Variable adrenocortical function in acute medical illness. Crit Car Med 1985 13:477-479
8. **Drucker D. J.**, Josse R. Non-neoplastic inappropriate TSH secretion with resistance to dopaminergic TSH inhibition. Clin Invest Med 1985 8:117-120
9. **Drucker D. J.**, Burrow G.N. Cardiovascular surgery in the hypothyroid patient. Arch Int Med 1985 145:1585-1587
10. Detsky A.S., Abrams H.B., McLaughlin J.R., **Drucker D. J.**, Sasson Z., Johnston N., Scott J.G., Forbath N., Hilliard J.R. Predicting cardiac complications in patients undergoing non-cardiac surgery. J. Gen Int Med 1986 1:211-219
11. **Drucker D.J.**, Mclaughlin J. Adrenocortical dysfunction in acute medical illness. Crit Care Med 1986 14:789-791
12. **Drucker D. J.**, Mojsov S., Habener J.F. Cell-specific posttranslational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene. J. Biol. Chem. 1986 261:9637-9643
13. Philippe J., Mojsov S., **Drucker D. J.**, Habener J.F. Proglucagon processing in a rat islet cell line resembles phenotype of intestine rather than pancreas. Endocrinology 1986 119:2833-2839
14. Philippe J., **Drucker D. J.**, Habener J.F. Glucagon gene transcription in an islet cell line is regulated via a protein kinase C activated pathway. J. Biol. Chem. 1987 262:1823-1828
15. Philippe J., **Drucker D. J.**, Habener J. F. Transcriptional regulation of genes encoding insulin, glucagon, and somatostatin by sodium butyrate in a rat cell line. Mol. Cell. Biol 1987 7:560-563
16. **Drucker D. J.**, Philippe J., Mojsov S., Chick W.L., Habener J.F. Insulinotropin: A novel glucagon related peptide stimulates insulin gene expression Proc. Natl. Acad. Sci (USA) 1987 84:3434-3438
17. **Drucker D. J.**, Philippe J., Jepeal L., Habener J.F. Cis-acting DNA sequence controls glucagon gene expression in pancreatic alpha cells Trans. Assoc. Amer. Phys.1987 vol C:109-115
18. **Drucker D. J.**, Philippe J., Jepeal L., and Habener J.F. Glucagon gene 5'-flanking sequences promote islet cell-specific gene transcription J. Biol. Chem. 1987 262:15659-15665

19. **Drucker D. J.**, Mojsov S., Philippe J., and Weir G. C. Cell-specific alternative post-translational processing of proglucagon. 1988, 1-14, Proceedings of the A. Benzon Symposium, Raven Press
20. Philippe J., **Drucker D. J.**, Knepel W., Jepeal L., and Habener J.F Alpha-cell specific expression of the glucagon gene is conferred to the glucagon promoter element by the interactions of DNA-binding proteins. *Mol. Cell. Biol.* 1988 8:4877-4888
21. Philippe J., Mojsov S., Powers A., **Drucker D. J.**, Comi R., Habener J.F. Expression of peptide hormone genes in human islet cell tumors. *Diabetes* 1988 37:1647-1651
22. **Drucker D. J.**, Philippe J., and Habener J. F. Regulation of glucagon gene expression. *Biomed. Res.* 1988 9:1-6.
23. **Drucker D. J.**, and Brubaker P. L. Glucagon biosynthesis in fetal rat intestine. *Biomed. Res.* 1988 9:29-32
24. **Drucker D. J.**, and Asa S. Glucagon gene expression in vertebrate brain. *J. Biol. Chem.* 1988 263:13475-1378
25. **Drucker D. J.**, Philippe J., and Mojsov S. Proglucagon gene expression and post-translational processing in a hamster islet cell line. *Endocrinology* 1988 123: 1861-1867
26. **Drucker D. J.**, and Brubaker P. Glucagon gene expression in rat intestine is regulated by a cyclic AMP-dependent pathway. *Proc. Natl. Acad. Sci (USA)* 1989 86:3953-3957
27. Brubaker P. L., So D. C. Y., and **Drucker D. J.** Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes. *Endocrinology* 1989 124:3003-3009
28. Siminoski K., Goss P., and **Drucker D. J.** Medroxyprogesterone acetate induced Cushings syndrome *Ann Intern Med* 1989 111: 758-760
29. **Drucker D. J.**, Asa S.L., Henderson, J., and Goltzman, D. The parathyroid-like protein gene is expressed in the normal and neoplastic human endocrine pancreas *Molecular Endocrinology* 1989 3:1589-1595
30. Lui E., Asa S., **Drucker D. J.**, and Brubaker P. L. Glucagon-related peptides in fetal rat hypothalamic cultures *Endocrinology* 1990 126:110-117
31. **Drucker D. J.**, Asa, S., Silverberg, J., and Brubaker, P.L. Molecular and cellular analysis of a neoplastic pancreatic A cell tumor. *Cancer* 1990 65:1762-1770
32. Rosen C. F., Gajic, D. and **Drucker D. J.** Ultraviolet B induction of ornithine decarboxylase gene expression. *Cancer Res* 1990, 50: 2631-5
33. Lee Y. C. and **Drucker D. J.** Glucagon gene 3'-flanking sequences direct formation of proglucagon mRNA 3'-ends in islet and non-islet cell lines. *Molecular Endocrinology* 1990, 4:800-806
34. Brubaker P. L., **Drucker D. J.**, and Greenberg G. Synthesis and secretion of somatostatin-28 by fetal rat intestinal cells in culture. *Am J Phys* 1990 258(6): G974-G981
35. McAuley P., Asa S. L., Chiu B., Henderson J., Goltzman D., and **Drucker D. J.** Parathyroid hormone-like peptide in normal and neoplastic mesothelial cells. *Cancer* 1990 66:1975-1979
36. Asa S.L., Henderson J., Goltzman D., and **Drucker D. J.** Parathyroid hormone-like peptide in normal and neoplastic human endocrine tissues. *J. Clin. Endocrinol. Metab* 1990 71:1112-1118
37. Rosen C.F., Gajic D., Qi J., and **Drucker D. J.** Ultraviolet B radiation induction of ornithine decarboxylase gene

expression in mouse epidermis. *Biochemical J.* 1990 270:565-568

38. **Drucker D. J.**, Bailey D., and Rotstein L. Thyroiditis as the presenting manifestation of disseminated extrapulmonary pneumocystis carinii infection. *J Clin Endocrinol Metab* 1990 87:1663-1665

39. Lee Y.C., Brubaker P.L. and **Drucker D. J.** Developmental and tissue-specific regulation of proglucagon gene expression *Endocrinology* 1990 127:2217-2222

40. **Drucker D. J.**, Campos R., Reynolds R., Stobie K., and Brubaker P. L. The rat glucagon gene is regulated by a cyclic AMP-dependent pathway in rat islet cells. *Endocrinology* 1991 128:394-400

41. Wang C., Campos R., Stobie K.M., Brubaker P.L., and **Drucker D. J.** Differential glucocorticoid regulation of glucagon gene expression in cell lines derived from rat and hamster islet cell tumors. *Cancer Res* 1991 51:1196-1201

42. Streuker C., and **Drucker D. J.** Rapid induction of parathyroid hormone-like peptide gene expression following islet cell differentiation. *Mol Endocrinol* 1991 5:703-708

43. Dong J., Asa S. L., and **Drucker D. J.** Islet cell and extrapancreatic expression of the LIM domain homeobox gene isl-1. *Mol Endocrinol* 1991 5:1633-1641

44. Brubaker P. L., **Drucker D. J.**, Asa S.L., and Greenberg G. R. Regulation of peptide YY synthesis and secretion in fetal rat intestinal cell cultures. *Endocrinology* 1991 129:3351-3358

45. Campos, R., Asa, S. L., and **Drucker D. J.** Immunocytochemical localization of parathyroid hormone-like peptide in the rat fetus. *Cancer Res* 1991 51: 6351-6357

46. Allinson, E.T. and **Drucker D. J.** Parathyroid hormone-like peptide (PLP) shares features with members of the early response gene family: rapid induction by serum, growth factors and cycloheximide. *Cancer Res* 1992 52:3103-3109

47. Lee, Y.C., Asa, S. L., and **Drucker D. J.** Glucagon gene 5'-flanking sequences direct expression of SV 40 large t antigen to the intestine producing carcinoma of the large bowel in transgenic mice. *J. Biol. Chem.* 1992 267:10705-10708

48. Rosen, C.F., Gajic, D., Jia, Q., and **Drucker D. J.** Interaction of TPA and ultraviolet B Radiation in the regulation of ODC gene expression in rat keratinocytes. *Am J Physiol Cell Physiol* 1992 263(5): C1103-C1110.

49. Campos, R.V., Wang, C., and **Drucker D. J.** Regulation of parathyroid hormone-related peptide gene transcription: Cell and tissue-specific promoter utilization mediated by multiple positive and negative DNA elements. *Mol Endocrinol* 1992 6:1642-1652

50. Brubaker, P.L., Lee, Y.C., and **Drucker D. J.** Alterations in proglucagon processing and inhibition of proglucagon gene expression in glucagon-SV 40 T antigen transgenic mice. *J. Biol. Chem.* 1992 267: 20728-20733

51. **Drucker D. J.**, Lee, Y.C., Asa, S.L., and Brubaker, P.L. Inhibition of pancreatic glucagon gene expression in mice bearing a subcutaneous glucagon-producing GLUtag transplantable tumour. *Mol. Endocrinol.* 1992 6:2175-2184

52. Gajic, D., **Drucker D. J.** Multiple cis-acting domains mediate basal and cAMP-dependent glucagon gene transcription in a mouse neuroendocrine cell line. *Endocrinology* 1993 132:1055-1060

53. Li, X., and **Drucker D. J.** Growth factor-like properties of parathyroid hormone-related peptide in transfected rodent cell lines. *Can Res* 1993 53:2980-2986

54. Lee, Y. C., Campos, R. V., and **Drucker D. J.** Region- and age-specific differences in proglucagon gene expression in the central nervous system of wild type and glucagon-SV 40 Tag transgenic mice. *Endocrinology* 1993 133:171-177

55. Roskams, T., Campos, R. V., **Drucker D. J.**, and Desmet, V.J. Reactive human bile ductules express parathyroid hormone-related peptide. *Histopathology* 1993 23:11-19
56. Roskams, T., Willems, M., Campos, R.V., **Drucker D. J.**, Yap, S.H., and Desmet, V.J. Parathyroid hormone-related peptide expression in primary and metastatic liver tumours. *Histopathology* 1993 23:519-525
57. Wang, M. and **Drucker D. J.** The Lim domain homeobox gene *isl-1*: Conservation of human, hamster and rat cDNA sequences and expression in cell types of neuroendocrine lineage. *Endocrinology* 1994 134:1416-1422
58. Campos, R.V., Lee, Y.C., and **Drucker D. J.** Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. *Endocrinology* 1994 134:2156-2164
59. Li, X., and **Drucker D. J.** Parathyroid hormone-related peptide is a downstream target for ras and src activation. *J. Biol. Chem.* 1994 269:6263-6266
60. Campos, R.V., Zhang, L., and **Drucker D. J.** Differential expression of RNA transcripts encoding unique carboxyterminal sequences of human PTHRP. *Mol Endocrinol* 1994 8:1656-1666
61. Ehrlich, P., Tucker, D., Asa, S.L., Brubaker, P.L., and **Drucker D. J.** Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous glucagon-producing endocrine tumors. *Am J Physiol* 1994 267:E662-E671
62. **Drucker D. J.** Molecular pathophysiology of glucagon-SV 40 T antigen transgenic mice. *Am J. Physiol* 1994 267:E629-E635
63. **Drucker D. J.**, Jin, T., Asa, S. L., Young, T. A., and Brubaker, P.L. Activation of proglucagon gene transcription by protein kinase A in a novel mouse enteroendocrine cell line. *Mol Endo* 1994 8:1646-1655
64. Rosen C.F., Poon R., and **Drucker D. J.** Identification of novel UVB-induced genes in rat keratinocytes. *Am. J. Physiol* 1995 268:C846-C855
65. Wang M., and **Drucker D. J.** The LIM domain homeobox gene *isl-1* is a positive regulator of islet cell-specific proglucagon gene transcription *J. Biol. Chem.* 1995 270:12646-12652
66. Jin T., and **Drucker D. J.** The proglucagon gene upstream enhancer contains positive and negative domains important for tissue-specific proglucagon gene transcription *Mol Endo* 1995 9:1306-1320
67. Jin T., and **Drucker D. J.** Activation of proglucagon gene transcription through a novel G1 promoter element by the *caudal*-related homeobox protein *cdx-3* *Mol Cell Biol* 1996 16: 19-28
68. Slingerland J. M., Petrocelli, T., Poon, R., **Drucker D. J.** and Rosen, C. F. UVB Radiation mediates S phase checkpoint via induction of p21 Cip/Waf1 Oncogene 1996 12:1387-1396
69. Wang M., and **Drucker D. J.** Activation of amylin gene transcription by the LIM domain homeobox gene *isl-1* *Mol Endo* 1996 10:243-251
70. Asa S.L., Lee, Y.C., and **Drucker, D. J.** Development of colonic and pancreatic endocrine tumors in mice expressing a glucagon-SV40 T antigen transgene *Virchows Archives* 1996 427:595-606
71. Shi Z.Q., Rastogi, K.S., Lekas, M., Efendic, S., **Drucker, D. J.**, and Vranic, M. Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats *Endocrinology* 1996 137:3193-3199
72. **Drucker D. J.**, Ehrlich, P., Asa, S. L., Brubaker, P. L. Induction of epithelial proliferation by glucagon-like peptide 2. *Proc. Natl. Acad. Sci.* 1996 93:7911-7916

73. Lu F., Jin, T., and **Drucker, D. J.** Proglucagon gene expression is induced by gastrin-releasing peptide in a mouse enteroendocrine cell line. *Endocrinology* 1996 137:3710-3716
74. Scrocchi, L. S., Brown, T. J., MacLusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L. and **Drucker, D. J.** Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene *Nature Medicine* 1996 2:1254-1258
75. Jin T., Trinh, D. K. Y., Wang, F., and **Drucker, D. J.** The *Caudal* homeobox gene *cdx-2/3* activates endogenous proglucagon gene expression in InR1-G9 islet cells *Mol Endocrinol* 1997 11:203-209
76. Chen E., and **Drucker, D. J.** Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. *J. Biol. Chem.* 1997 272:4108-4115
77. Tsai C.-H., Hill, M., and **Drucker, D. J.** Biological determinants of intestinotrophic properties of GLP-2 *in vivo* *Am. J. Physiol.* 1997 272:G662-G668
78. Brubaker, P.L. Izzo, A., Hill, M., and **Drucker, D. J.** Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. *Am. J. Physiol.* 1997 272: E1050 - E1058
79. Tsai A., Hill, M., Asa, S. L., Brubaker, P.L., and **Drucker, D.J.** Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. *Am. J. Physiol.* 1997 Jul;273(1 Pt 1):E77-84
80. **Drucker D. J.**, Shi, Q., Crivici, A., Sumner-Smith, M., Tavares, W., Hill, M. DeForest, L., Cooper, S., and Brubaker, P.L. Regulation of the biological activity of glucagon-like peptide 2 *in vivo* by dipeptidyl peptidase IV *Nature Biotechnology* 1997 15:673-677
81. Fischer K.D., Dhanvantari, S., **Drucker, D.J.** and Brubaker, P.L. Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats *Am. J. Physiol.* 1997 273:E815-E820
82. Brubaker P.L., Crivici, A., Izzo, A., Ehrlich, P., Tsai, A. and **Drucker, D. J.** Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2 *Endocrinology* 1997 138:4837-4843
83. **Drucker D. J.**, DeForest, L., and Brubaker, P.L. Intestinal response to growth factors administered alone or in combination with h[Gly2]-GLP-2 *Am. J. Physiol.* 1997 273:G1252-G1262
84. Scrocchi L. A., Brown, T. J., and **Drucker, D. J.** Leptin sensitivity in non-obese GLP-1 receptor-/- mice *Diabetes* 1997 46: 2029-2034
85. Flamez, D., Breusegem, A.V., Scrocchi, L. A., Quartier, E., Pipeleers, D., **Drucker, D. J.**, Schuit, F. Mouse pancreatic β cells exhibit preserved glucose competence after disruption of the GLP-1 Receptor gene 1998 *Diabetes* 47: 646-652
86. Scrocchi, L. A., Marshall, B. A., Cook, S. M., Brubaker, P. L., and **Drucker, D. J.** Glucose homeostasis in mice with disruption of GLP-1 receptor signaling 1998 *Diabetes* 47: 632-639
87. Scrocchi, L. A. and **Drucker D. J.** Effects of aging and a high fat diet on body weight and glucose tolerance in GLP-1R-/- mice 1998 *Endocrinology* 139:3127-32
88. Pederson, R.A., Satkunarajah, M., McIntosh, C. H. S., Scrocchi, L. A., Flamez, D., Schuit, F., **Drucker, D. J.** and Wheeler, M.B. Plasticity in the enteroinsular axis is characterized by enhanced GIP secretion and insulinotropic action in GLP-1R-/- mice 1998 *Diabetes* 47:1046-52.
89. Brubaker, P.L., Schloos, J., and **Drucker, D. J.** Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line 1998 *Endocrinology* 139:4108-4114

90. Serre, V., Dolci, W., Scrocchi, L.A., **Drucker, D. J.**, Efrat, S., and Thorens, B. Exendin-(9-39) as an inverse agonist of the GLP-1 receptor. Implications for basal intracellular cAMP levels and β cell glucose competence 1998 *Endocrinology* 139(11):4448-54
91. **Drucker, D. J.**, DeForest, L., Yusta, B., Boushey, R. P. and Brubaker, P. L. Enhancement of intestinal epithelial repair by h[Gly2]-GLP-2 in a murine model of ulcerative colitis 1999 *Am J Physiol* 276:G79-G91
92. Munroe, D. G. Gupta, A. K., Kooshesh, P., Vyas, T. B., Rizkalla, G., Wang, H., Demchyshyn, L., Kamboj, R. K., McCallum, K., Sumner-Smith, M., **Drucker, D. J.**, Crivici, A. Prototypic G protein coupled receptor for the intestinotrophic factor glucagon-like peptide 2 1999 *Proc. Natl. Acad. Sci (USA)* 96:1569-1573
93. Kaestner, K.H., Katz, K., Liu, Y., **Drucker, D. J.** and Schutz, G. Inactivation of the winged helix transcription factor HNF3 α affects glucose homeostasis and islet glucagon gene expression *in vivo* 1999 *Genes & Development* 13:495-504
94. Trinh, D., Jin, T., and **Drucker, D. J.** Identification of domains mediating transcriptional activation and cytoplasmic export in the *caudal* homeobox protein Cdx-3 1999 *J. Biol. Chem.* 274:6011-6019
95. Xiao, Q., Boushey, R.P., **Drucker, D. J.**, and Brubaker, P.L. Secretion of the intestinotropic hormone glucagon-like peptide-2 is differentially regulated by nutrients in humans 1999 *Gastroenterology* 117:99-105
96. Hill, M.E., Asa, S.L., and **Drucker, D. J.** Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription 1999 *Mol Endocrinol* 13(9):1474-86
97. Flamez, D., Gilon, P., Moens, K., Van Breusegem, A., Delmeire, D., Scrocchi, L.A., Henquin, J.C., **Drucker, D. J.**, and Frans Schuit. Altered cAMP and Ca²⁺ signaling in mouse pancreatic islets with GLP-1 receptor null phenotype 1999 *Diabetes* 48:1979-1986
98. Yusta, B., Somwar, R., Wang, F., Munroe, D., Grinstein, S., Klip, A., and **Drucker, D. J.** Identification of GLP-2 activated signaling pathways in BHK fibroblasts expressing the rat GLP-2 receptor 1999 *J. Biol. Chem.* 274:30459-30467
99. Boushey, R. P. Yusta, B., and **Drucker, D. J.** GLP-2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. 1999 *Am J Physiol* 277: E937-E947
100. Nian, M., **Drucker, D. J.**, Irwin D. Divergent regulation of human and rat proglucagon gene promoters *in vivo*. 1999 *Am J Physiol* 277:G829-37
101. Tavares, W., **Drucker, D. J.** and Brubaker, P.L. Enzymatic and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in the rat. 2000 *Am J Physiol* 278:E134-E139
102. MacLusky, N. J., Cook, S., Scrocchi, L. A., Shin, J., Kim, J., Vaccarino, F., Asa, S. L. and **Drucker, D. J.** Neuroendocrine function in mice with complete disruption of GLP-1 receptor signaling *Endocrinology* 2000 141:752-62.
103. Xiao, Q., Boushey, R. P., Cino, M. **Drucker, D. J.**, and Brubaker, P.L. Circulating levels of GLP-2 in human subjects with inflammatory bowel disease 2000 *Am J Physiol* 278(4):R1057-R1063
104. Stoffers, D.A., Kieffer, T.J., Hussain, M. H., **Drucker, D. J.**, Egan, J.M., Bonner-Weir, S., Habener, J.F. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β cell mass in mouse pancreas 2000 *Diabetes* 49:741-748
105. Marguet, D., Baggio, L., Kobayashi, T., Bernard, A-M., Pierres, M., Nielsen, P.F., Ribel, U., Watanabe, T., **Drucker, D. J.**, and Wagtmann, N. Enhanced insulin secretion and accelerated blood glucose clearance in mice lacking CD26 2000 *Proc. Natl. Acad. Sci. USA.* 97(12):6874-6879

106. Elias, C.F., Kelly, J.F., Lee, C.E., Ahima, R.S., **Drucker, D. J.**, Saper, C.B., and Elmquist, J.K. Chemical characterization of leptin-activated neurons in the rat brain *Journal of Comparative Neurology* 2000 43:261-281
107. DaCambre, M.P. Yusta, B., Sumner-Smith, M., Crivici, A., Brubaker, P.L., **Drucker, D. J.** Structural determinants for activity of glucagon-like peptide-2. 2000 *Biochemistry* 39: 8888-8894
108. Yusta, B., Huang, L., Munroe, D., Wolff, G., Fantaske, G., Demchyshyn, L., Asa, S. L., and **Drucker, D. J.** Enteroendocrine Localization of GLP-2 Receptor Expression in Humans and Rodents 2000 *Gastroenterology* 119: 744-755
109. Scrocchi, L. A., Hill, M. E., Saleh, J., Perkins, B., and **Drucker, D. J.** Elimination of GLP-1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action 2000 *Diabetes* 49:1552-1560
110. Baggio, L., Kieffer, T.J., and **Drucker, D. J.** GLP-1 but not GIP regulates fasting glycemia and non-enteral glucose clearance in mice *Endocrinology* 2000 Oct;141(10):3703-9.
111. Lovshin, J., Yusta, B., Iliopoulos, I., Migirdicyan, A., Dableh, L., Brubaker, P.L., and **Drucker, D. J.** Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. *Endocrinology* 2000 141: 4194-4201
112. Yusta, B., Boushey, R. P., **Drucker, D. J.** The Glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a PKA-independent pathway *J. Biol. Chem.* 2000 275: 35345-35352
113. Baggio, L., Adatia, F., Bock, T., Brubaker, P. L., **Drucker, D. J.** Sustained expression of exendin-4 does not perturb glucose homeostasis, β cell mass or food intake in metallothionein-preproexendin transgenic mice *J. Biol. Chem.* 2000 275: 34471-34477
114. Boushey, R.P., Yusta, B., and **Drucker, D. J.** Glucagon-like Peptide (GLP)-2 Reduces Chemotherapy-associated Mortality and Enhances Cell Survival in Cells Expressing a Transfected GLP-2 Receptor *Cancer Res* 2001 61: 687-693
115. Lefebvre D. L., Bai Y., Shahmolky N., Sharma M., Poon R., **Drucker D. J.**, Rosen C.F. Identification and characterization of a novel sucrose-non-fermenting protein kinase/AMP-activated protein kinase-related protein kinase, SNARK. 2001 *Biochem J* Apr 15;355(Pt 2):297-305
116. Lovshin J, Estall J, Yusta B, Brown T. J., **Drucker D. J.** Glucagon-like peptide-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. 2001 *J Biol Chem.* 276(24):21489-99.
117. Ling Z, Wu D, Zambre Y, Flamez D, **Drucker D. J.**, Pipeleers D.G., Schuit F.C. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. 2001 *Virchows Arch* Apr;438(4):382-7
118. Burcelin, R., Da Costa, A., **Drucker, D.J.**, and Thorens, B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. 2001 *Diabetes.* 50(8):1720-8
119. Nian, M., Gu, J., Irwin, D.M., and **Drucker, D. J.** Human glucagon gene promoter sequences regulating tissue-specific versus nutrient-regulated gene expression. 2002 *Am J Physiol Regul Integr Comp Physiol.* 282(1):R173-83
120. Yusta, B., Estall, J., and **Drucker, D. J.** GLP-2 receptor activation engages Bad and glycogen synthase kinase 3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase 2002 *J Biol Chem* 277(28):24896-906
121. Brubaker, P.L., **Drucker, D. J.**, Asa, S. L., Swallow, C., Redston, M., Greenberg, G. R. Prolonged gastrointestinal transit in a patient with a glucagon-like peptide-1- and glucagon-like peptide-2-producing neuroendocrine tumor 2002 *JCEM* 87(7):3078-3083

122. Liu, Y., Shen, W., Brubaker, P. L., Kaestner, K. H., and **Drucker, D. J.** Foxa3 (HNF-3 γ) binds to and activates the rat proglucagon gene promoter but is not essential for proglucagon gene expression 2002 *Biochemical Journal* 366:633-641
123. Yamamoto, H., Lee, C.E., Marcus, J.N., Williams, T.D., Overton, J.M., Lopez, M. E., Hollenberg, A.N., Baggio, L., **Drucker, D.J.**, and Elmquist, J. K. A. Glucagon-like peptide-1 receptor agonist increases blood pressure and heart rate, and activates autonomic regulatory neurons 2002 *J Clin Invest* 110:43-52
124. Adatia, F. A., Baggio, L. L., Xiao, Q., **Drucker, D. J.**, and Brubaker, P. L. Cellular specificity of proexendin-4 processing in mammalian cells *in vitro* and *in vivo*. *Endocrinology* 2002 143: 3464-3471
125. Flock, G., and **Drucker, D. J.** Pax-2 activates the proglucagon gene promoter but is not essential for proglucagon gene expression or development of proglucagon-producing cell lineages in the murine pancreas or intestine. *Mol Endocrinol* 2002 16(10):2349-59
126. Li, Y., Hansotia, T., Yusta B., Ris, F., Halban, P. A., and **Drucker D. J.** Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. *J Biol Chem* 2003 278(1):471-8
127. Trinh, K.Y.T., Zhang, K., Hossain, M., Brubaker, P. L., and **Drucker, D. J.** Pax-6 activates endogenous proglucagon gene expression in the rodent gastrointestinal epithelium *Diabetes* 2003 Feb;52(2):425-33.
128. DeLeon, D. D., Deng, S., Madani, R., Ahima, R., **Drucker, D. J.**, Stoffers, D. A. Role of Endogenous Glucagon-Like Peptide-1 (GLP-1) in Islet Regeneration after Partial Pancreatectomy *Diabetes* 2003 Feb;52(2):365-371.
129. Yamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., **Drucker, D. J.**, Saper, C.B., and Elmquist, J. K. Glucagon-like Peptide-1 Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-like Peptide-1 with Central Autonomic Control Sites. *J. Neurosci Res* 2003 Apr 1;23(7):2939-46
130. Kim, J.-G., Baggio, L. L., Bridon, D. P., Castaigne, J.-P., Robitaille, M. F., Jette, L., Benquet, C., and **Drucker, D. J.** Development and characterization of a GLP-1-albumin conjugate which retains the ability to activate the GLP-1 receptor *in vivo*. *Diabetes* 2003 52(3):751-9
131. Cao, X., Flock, G., Choi, C., Irwin, D. M., and **Drucker, D. J.** Aberrant regulation of human intestinal proglucagon gene expression in the NCI-H716 cell line. *Endocrinology* 2003 May;144(5):2025-33
132. Gros, R., You, X., Baggio, L. L., Kabir, M. G., Sadi, A-M., Mungrue, I. N., Parker, T. G., Huang, Q., **Drucker, D. J.**, and Husain, M. Cardiac function in mice lacking the GLP-1 receptor *Endocrinology* 2003 144(6) 2242-2252
133. Boushey, R. P., Abadir, A., Flamez, D., Baggio, L. L., Li, Y., Berger, V., Marshall, B. A., Finegood, D., Wang, T. C., Schuit, F., and **Drucker, D. J.** Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene *Gastroenterology* 2003 125:1164-174
134. Walsh, N. A., Yusta, B., DaCambra, M. P., Anini, Y., **Drucker D. J.**, and Brubaker P. L. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa *Endocrinology* 2003 Oct;144(10):4385-92
135. During M.J., Cao L, Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., Bland R.J., Klugmann M., Banks W.A., **Drucker D.J.**, Haile C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. *Nat Med.* 2003 Sep;9(9):1173-1179
136. Preitner, F., Ibberson, M., Franklin, I., Binnert, C., Pende, M., Gjinojci, A., Hansotia, T., **Drucker, D. J.**, Wollheim, C., Burcelin, R., Thorens, B. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors *J Clin Invest* 2004 113:635-645.

137. Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Preitner, F., Yamada, Y., Tsukiyama, K., Thorens, B., Seino, Y., Holst, J. J., Schuit, F., and **Drucker, D. J.** Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory action of DPP-IV inhibitors Diabetes 2004 May;53(5):1326-1335
138. Baggio, L. L., Huang, Q., Brown, T. J., and **Drucker, D. J.** Oxyntomodulin activates both the glucagon and glucagon-like peptide-1 (GLP-1) receptors but exerts anorectic effects in mice via the GLP-1 receptor Gastroenterology 2004 Aug;127(2):546-58
139. Lovshin, J. A., Huang, Q., Seaberg, R., Brubaker, P. L., and **Drucker, D. J.** Extrahypothalamic expression of the Glucagon-like Peptide-2 (GLP-2) receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells Endocrinology 2004 Jul;145(7):3495-506.
140. Estall, J. L., Yusta, B., and **Drucker, D. J.** Lipid raft-dependent GLP-2 receptor trafficking occurs independently of agonist-induced desensitization Molecular Biology of the Cell 2004 Aug;15(8):3673-87
141. Baggio, L. L., Huang, Q., Brown, T. J., and **Drucker, D. J.** A recombinant human GLP-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1R-dependent pathways coupled to satiety, gastrointestinal motility, and glucose homeostasis Diabetes 2004 Sep;53(9):2492-500.
142. Baggio, L. L., Kim, G.-K., and **Drucker, D. J.** Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization *in vitro* but does not attenuate GLP-1R-dependent glucose homeostasis *in vivo* Diabetes. 2004 Dec;53 Suppl 3:S205-14.
143. Koehler, J., Yusta, B., and **Drucker, D. J.** The HeLa cell GLP-2 receptor is coupled to regulation of apoptosis and Erk1/2 activation through divergent signaling pathway Mol Endocrinol 2005 Feb;19(2):459-73
144. Flock, G., Cao, X., and **Drucker, D. J.** Pdx-1 is not sufficient for repression of proglucagon gene transcription in islet or enteroendocrine cells Endocrinology 2005 146:441-449
145. Lachey, J. L., D'Alessio, D. A., Rinaman, L., Elmquist, J. K., **Drucker, D. J.**, Seeley, R. J. The role of central GLP-1 in mediating the effects of visceral illness: Differential effects in rats and mice Endocrinology 2005 146: 458-462
146. Li, Y., Cao, X., Li, L.-X., Brubaker, P. L., Edlund, H., **Drucker, D. J.** Beta cell Pdx1 expression is essential for the glucoregulatory proliferative and cytoprotective actions of glucagon-like peptide-1 Diabetes. 2005 Feb;54(2):482-91
147. Reimann, F., Maziarz, M., Flock, G., Habib, A. M., **Drucker, D. J.** and Gribble, F. M. Characterisation and functional role of voltage gated cation conductances in the Glucagon-like peptide-1 secreting GLUTag cell J Physiol. 2005 Feb 15;563(Pt 1):161-75
148. Shin, E. D., Estall, J., Izzo, A., **Drucker, D. J.**, and Brubaker, P. L. Mucosal adaptation to enteral nutrients is dependent on the physiological actions of GLP-2 in mice. Gastroenterology 2005 May;128(5):1340-53
149. Maziarz, M., Chung, C., **Drucker, D. J.**, and Emili, A. Integrating global proteomic and genomic expression profiles generated from islet α cells: Opportunities and challenges to deriving reliable biological inferences. Mol Cell Proteomics. 2005 Apr;4(4):458-474.
150. Estall, J. E., Koehler, J. A., Yusta, B., and **Drucker, D. J.** The GLP-2R C-terminus modulates beta-arrestin-2 association, but is dispensable for ligand-induced desensitization, endocytosis and G-protein-dependent effector activation. J Biol Chem. 2005 Jun 10;280(23):22124-34
151. Schonhoff, S., Baggio, L., Ratineau, C., Ray, S. K., Lindner, J., Magnuson, M.A., **Drucker, D. J.**, and Leiter, A.B. Energy Homeostasis and Gastrointestinal Endocrine Differentiation Do Not Require the Anorectic Hormone Peptide YY Mol. Cell. Biol. 2005 25: 4189-4199

152. Talsania, T., Anini, Y., Siu, S., **Drucker, D. J.**, Brubaker, P. L. Peripheral Exendin-4 and PYY3-36 synergistically reduce food intake through different mechanisms in mice *Endocrinology* 2005 146:3748-3756
153. Knauf, C., Perrin, C., Cani, P. D., Iglesias, M. A., Maury, J. F., Bernard, E., Benhamed, F., Grémeaux, T., **Drucker, D. J.**, Kahn, C. R., Girard, J., Tanti, J. F., Delzenne, N. M., Postic, C. M., Burcelin, R. M. Brain Glucagon-Like Peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage *J Clin Invest* 2005 115(12):3554-3563.
154. Koehler, J.A., and **Drucker, D. J.** Activation of GLP-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells *Diabetes* 2006 55: 1369-1379
155. Cani, P. D., Iglesias, M. A., **Drucker, D. J.**, Delzenne, N. M., and Burcelin, R. Improvement of Glucose Tolerance and Hepatic Insulin Sensitivity by Oligofructose Requires a Functional Glucagon-Like Peptide 1 Receptor *Diabetes* 2006 55: 1484-1490
156. Baggio, L. L., Holland, D. Wither, J., and **Drucker, D. J.** Lymphocytic infiltration and immune activation in metallothionein promoter-exendin-4 (MT-Exendin) transgenic mice *Diabetes* 2006 June;55(6):1562-70
157. Yusta, B., Baggio, L. L., Estall, J. E., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., and **Drucker, D. J.** GLP-1 receptor activation improves β -cell function and survival following induction of endoplasmic reticulum stress *Cell Metabolism* 2006 Nov;4(5):391-406
158. Sowden, G. L., **Drucker, D. J.**, Weinshenker, D., Swoap, S. J. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor *The American Journal of Physiology - Regulatory, Integrative and Comparative Physiology* 2007 Feb;292(2):R962-70.
159. Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, S., and **Drucker, D. J.** Extrapancreatic incretin receptors modulate glucose homeostasis and energy expenditure *J Clin Invest* 2007 January 2; 117(1): 143–152.
160. Cani, P. D., Holst, J.J., **Drucker, D. J.**, Delzenne, N. M., Thorens, B., Burcelin, R., and Knauf, C. GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. *Mol Cell Endocrinol* 2007 Sep 30;276(1-2):18-23
161. Wideman, R. D., Covey, S. D., Webb, G. C., **Drucker D. J.**, and Kieffer, T. J. A Switch from PC2 to PC1/3 Expression in Transplanted α -cells is Accompanied by Differential Processing of Proglucagon and Improved Glucose Homeostasis in Mice *Diabetes* 2007: 56:2744-2752
162. MacAulay, K., Doble, B. W., Patel, S., Hansotia, T., Sinclair, E. M., **Drucker, D. J.**, Nagy, A., and Woodgett, J. R. Glycogen synthase kinase-3 α specific regulation of murine hepatic glycogen metabolism *Cell Metabolism* 2007 Oct;6(4):329-37
163. Flock, G., Baggio, L. L., Longuet, C., and **Drucker, D. J.** The incretin receptors for GLP-1 and GIP are essential for the sustained metabolic actions of vildagliptin in mice *Diabetes* 2007;56:3006-3013
164. Lamont, B., and **Drucker, D. J.** Differential anti-diabetic efficacy of incretin agonists vs. DPP-4 inhibition in high fat fed mice *Diabetes* 2008;57:190 -198.
165. Ayala, J. E., Bracy, D. P., Hansotia, T., Flock, G., Seino, Y., Wasserman, D. H., and **Drucker, D. J.** Insulin action in the double incretin receptor knockout mouse *Diabetes* 2008 57: 288 -297
166. Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., **Drucker, D. J.**, Seino, Y., and Inagaki, N. The murine Glp1r is essential for control of bone resorption *Endocrinology* 2008 149: 574-579

167. Hadjiyanni, I., Baggio, L. L., Poussier, P., and **Drucker D. J.** Exendin-4 modulates diabetes onset in non obese diabetic mice. *Endocrinology*. 2008 Mar;149(3):1338-49.
168. Baggio, L. L., Cao, X., Huang, Q., and **Drucker, D. J.** An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis *Gastroenterology* 2008 Apr; 134(4): 1137-47.
169. Kumar, K. G., Byerley, L., Volaufova, J., **Drucker, D. J.**, Churchill, G. A., Li, R., York, B., Zuberi, A., Smith Richards, B. K. Genetic variation in Glp1r expression influences the rate of gastric emptying in mice. *Am J Physiol Regul Integr Comp Physiol*. 2008 Feb;294(2):R362-71.
170. Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., **Drucker, D. J.**, and Husain, M. Cardioprotective and vasodilatory actions of GLP-1 are mediated through both GLP-1 receptor-dependent and independent pathways *Circulation* 2008 May 6;117(18):2340-50.
171. Shin, Y. K., Martin, B., Golden, E., Dostson, C. D., Maudsely, S., Kim, W., Jang, H. J., Mattson, M. P., **Drucker, D. J.**, Egan, J. M., and Munger, S. D. Modulation of taste sensitivity by GLP-1 signaling *J. Neurochem* April 2008 106:455-463
172. Picha, K. M., Cunningham, M. R., **Drucker, D. J.**, Mathur, A., Ort, T., Scully, M., Soderman, A., Spinka-Doms, T., Stojanovic-susulic, V., Thomas, B. A., and O'Neil, T. Protein engineering strategies for sustained GLP-1R-dependent control of glucose homeostasis *Diabetes* 2008 57:1926-1934
173. Knauf, C., Cani, P. D., Kim, D.-H., Iglesias, M. A., Chabo, C., Waget, A., Colom, A., Rastrelli, S., Delzenne, N.M., **Drucker, D. J.**, Seeley, R. J., and Burcelin, R. The role of CNS GLP-1 receptors in enteric glucose sensing *Diabetes* 2008 57:2603-2612
174. Koehler, J. K., Harper, W., Barnard, M., Yusta, B., **Drucker, D. J.** Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells *Can Res* 2008 68:7897-7904
175. **Drucker, D. J.**, Buse, J.B., Taylor, K., Kendall, D., Trautmann, M., Zhuang, D., Porter, L. 2008 Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study *Lancet* 2008 372:1240-50
176. Maida, A., Lovshin, J. L., Baggio, L.L. and **Drucker D. J.** The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances β -cell function but does not inhibit gastric emptying in mice *Endocrinology* 2008 149;5670-5678
177. Cabou, C., Campistron, Marsollier, G. N., Corinne Leloup, C., Cruciani-Guglielmacci, C., Pénicaud, L., **Drucker, D. J.**, Magnan, C., and Burcelin, R. Brain GLP-1 regulates arterial blood flow, heart rate and insulin sensitivity *Diabetes*. 2008 Oct;57(10):2577-87.
178. Sinclair, E.M., Yusta, B., Streutker, C., Baggio, L.L., Koehler, J., Charron, M.J., and **Drucker D. J.** Glucagon receptor signaling is essential for control of murine hepatocyte survival *Gastroenterology* 2008 Dec;135(6):2096-2106.
179. Patel, S., Doble, B. W., MacAulay, K., Sinclair, E. M. **Drucker, D. J.** and. Woodgett, J. R. Tissue-specific role of glycogen synthase kinase-3 β in glucose homeostasis and insulin action *Mol. Cell. Biol*. 2008;28(20)6314-6328
180. Longuet, C., Sinclair, E.M., Maida, A., Baggio, L.L., Maziarz, M., Charron, M.J., and **Drucker, D. J.** Glucagon is essential for control of hepatic lipid metabolism and the adaptive metabolic response to fasting *Cell Metabolism* 2008;8: 359-371

181. Duez H., Smith A.C., Xiao C., Giacca A., Szeto L., **Drucker D. J.**, Lewis G.F. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice *Endocrinology* 2009 Jan;150(1):56-62
182. Hadjiyanni, I., Li, K. K., and **Drucker D. J.** Glucagon like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the non obese diabetic mouse *Endocrinology* 2009 Feb;150(2):592-9
183. Ayala, J., Bracy, D. P., James, F. D., Julien, B. M., Wasserman, D. H., and **Drucker, D. J.** The Glucagon-like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of its Incretin Action *Endocrinology* 2009 Mar;150(3):1155-64
184. Noyan-Ashraf M. H., Momen M. A., Ban K., Sadi A. M., Zhou Y. Q., Riazi, A. M., Baggio L. L., Henkelman R.M., Husain M., **Drucker D. J.** The GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes following experimental myocardial infarction in mice. *Diabetes* 2009 Apr;58(4):975-83.
185. Hsieh J., Longuet C., Maida A., Bahrami J., Xu E., Baker C.L., Brubaker P.L., **Drucker D. J.**, Adeli K. Glucagon-like Peptide-2 Increases Intestinal Lipid Absorption and Chylomicron Production via CD36 *Gastroenterology*. 2009 Sep;137(3):997-1005.
186. Koehler J.A., Baggio L.L., Lamont B.J., Ali S., **Drucker D. J.** GLP-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice *Diabetes* 2009 58:2148-2161
187. Day, J., Ottaway, N., Patterson, J., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., **Drucker, D. J.**, Chaudhary, N., Holland, J., Hembree, J., Abplanalp, W., Grant, E., Ruehl, J., Wilson, H., Kirchner, H., Lockie, S., Hofmann, S., Woods, S., Nogueiras, R., Pfluger, P., Perez-Tilve, D., DiMarchi, R., and Tschop, M. A novel glucagon/GLP-1 co-agonist eliminates obesity in rodents *Nature Chemical Biology* 2009 Oct;5(10):749-57.
188. Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, Z., Mastronardi, F., Maezawa, Y., **Drucker, D. J.**, Engleman, E., Winer, D., and Dosch, H.-M. Normalization of obesity-associated insulin resistance through immunotherapy *Nature Medicine* 2009 (15) 921-929.
189. Yusta B., Holland D., Koehler J.A., Maziarz M., Estall J.L., Higgins R., **Drucker D. J.** ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut *Gastroenterology* 2009 Sep;137(3):986-96.
190. Belsham, D. D., Fick, L. J., Dalvia, P. S., Centeno, M.-L., Chalmers, J. A., Lee, P. K. P., Yang, Y., **Drucker, D. J.**, and Koletar, M. M. Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis allowing immortalization of adult murine hypothalamic neurons *FASEB J.* 2009 Dec; 23 (12):4256-65.
191. Maida, A., Hansotia, T., Longuet, C., Seino, Y., **Drucker, D. J.** Differential importance of GIP vs. GLP-1 receptor signaling for beta cell survival in mice *Gastroenterology* 2009 137 (6), 2146-2157
192. Barrera, J. G., D'Alessio, D. A., **Drucker, D. J.**, Woods, S. C., and Seeley, R. J. Differences in the central anorectic effects of GLP-1 and exendin-4 in rats *Diabetes* 2009 Dec;58(12):2820-7.
193. Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., **Drucker, D. J.**, Adeli, K. The glucagon-like peptide-1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice *Diabetologia* 2010 Mar;53(3):552-61.
194. Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., **Drucker D. J.** Glucagon-like peptide-1 receptor (GLP-1R) signaling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T-cells *Diabetologia* 2010 Apr;53(4):730-40.

195. Ban, K., Kim, K.-H., Cho, C.-K., Sauvé, S., Diamandis, E. P., Backx, P. H., **Drucker, D. J.**, and Husain, M. GLP-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor *Endocrinology* 2010 Apr;151(4):1520-31.
196. Sauve, M., Ban, K., Momen, M. A., Zhou, Y-Q., Henkelman, R. M., Husain, M., and **Drucker, D. J.** Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice *Diabetes* 2010 Apr;59(4):1063-73
197. Knudsen, L. B., Madsen, L.W., Andersen, S., Almholt, K., de Boer, A. S., **Drucker, D. J.**, Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., Jacobsen, S. D., Moses, A. C., Molck, A. M., Nielsen, H. S., Nowak, J., Solberg, H., Thi, T. D. L., Zdravkovic, M. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation *Endocrinology* 2010 Apr;151(4):1473-86.
198. Buse, J. B., **Drucker, D. J.**, Taylor, K. L., Kim, T., Walsh, B., Hu, H., Wilhelm, K., Trautmann, M., Shen, L. Z., Porter, L. E., and the DURATION 1 Study Group DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks *Diabetes Care* June;33(6):1255-61
199. Bahrami, J., Yusta, B., and **Drucker, D. J.** ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel *Gastroenterology* 2010 Jun;138(7):2447-56.
200. Bahrami, J., Longuet, C., Baggio, L.L., Li, K., and **Drucker, D. J.** Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse *Gastroenterology* 2010 Sep;139(3):857-868
201. Ayala, J. E., Bracy, D. P., James, F. D., Burmeister, M. A., Wasserman, D. H. and **Drucker, D. J.** Glucagon-like Peptide-1 Receptor Knockout Mice are Protected from High Fat Diet-Induced Insulin Resistance Independent of Effects on Body Composition *Endocrinology* 2010 Oct;151(10):4678-87
202. Maida, A., Lamont, B. J., Cao, X., and **Drucker, D. J.** Metformin regulates the incretin receptor axis via a peroxisome proliferator-activated receptor α -dependent pathway in mice *Diabetologia* 2011 Feb;54(2):339-49
203. Flock, G., Cao, X., Seino, Y., and **Drucker, D. J.** GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms *Endocrinology* 2011 152(2) 374-83
204. Kyle, K.A., Willett, T.L., Baggio, L.L., **Drucker, D. J.**, Grynepas, M. Differential Effects of PPAR- γ Activation vs. Chemical or Genetic reduction of DPP-4 Activity on Bone Quality in Mice *Endocrinology* 2011 152(2) 457-67
205. Ali, S., Lamont, B.J., Charron, M., and **Drucker D. J.** Dual elimination of the glucagon and Glp-1 receptors in mice reveals plasticity in the incretin axis *J Clinical Investigation* 2011 121(5) 1917-29
206. Waget, A., Cabou, C., Masseboeuf, M., Cattan, P., Armanet, M., Karaca, M., Castel, J., Garret, C., Payros, G., Maida, A., Sulpice, T., Holst, J.J., **Drucker, D. J.**, Magnan, C., Burcelin, R. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice *Endocrinology* 2011 Aug;152(8):3018-29
207. Dao T. M., Waget A., Klopp P., Serino M., Vachoux C., Pechere L., **Drucker D. J.**, Champion S., Barthélemy S., Barra Y., Burcelin R., Séré E. Resveratrol Increases Glucose Induced GLP-1 Secretion in Mice: A Mechanism which Contributes to the Glycemic Control *PLoS One*. 2011;6(6):e20700.
208. Koehler, J. A., Kain, T., **Drucker, D. J.** Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells *Endocrinology* 2011 Sep;152(9):3362-72.
209. Chen, M., Mema, E., Kelleher, Nemechek, J. N., Berger, A., Wang, J., Xie, T., Gavrilova, O., **Drucker, D. J.**, Weinstein, L. S. Absence of the Glucagon-Like Peptide-1 Receptor Does Not Affect the Metabolic Phenotype of Mice with Liver-Specific G α s Deficiency *Endocrinology* 2011 Sep;152(9):3343-50

210. Cabou, C., Vachoux, C., Campistron, G., **Drucker, D. J.** and Burcelin, R. Brain GLP-1 signaling regulates controls femoral artery blood flow and insulin sensitivity through hypothalamic PKC- δ Diabetes 2011 September 2011 60:2245-2256
211. Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., Fukami, A., Hamada, Y., Inagaki, N., Seino, Y., **Drucker, D. J.**, Oiso, Y., and Nakamura, J. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice Diabetes 2011 60:2397-2406
212. Barthson, J., Germano, C.M., Moore, F., Maida, A., **Drucker, D.J.** Marchetti, P., Gysemans, C., Mathieu, C., Nuñez, G., Jurisicova, A., Eizirik, D.L., Gurzov, E.N., Tumor necrosis factor- α and interferon- γ induce pancreatic β -cell apoptosis through STAT1-mediated bim activation J. Biol. Chem. 2011 Nov 11; 286(45): 39632-43
213. Ellingsgaard, H., Hauselmann, I., Schuler, B., Habib, A. M., Baggio, L. L., Meier, D. T., Eppler, E., Bouzakri, K., Wueest, S., Muller, Y. D., Hansen, A. M., Reinecke, M., Konrad, D., Gassmann, M., Reimann, F., Halban, P. A., Gromada, J., **Drucker, D. J.**, Gribble, F. M., Ehses, J. A., and Donath, M. Y. Interleukin-6 enhances insulin secretion by increasing L cell and α cell glucagon-like peptide-1 secretion Nature Medicine 2011 Oct 30;17(11):1481-9.
214. Bates, H., Campbell, J. E., Ussher, J. R., Baggio, L. L., Maida, A., Seino, Y., and **Drucker D. J.** The Gpr is essential for adrenocortical steroidogenesis however corticosterone deficiency does not mediate the favourable metabolic phenotype of *Gipr*^{-/-} mice Diabetes 2012 61:40-48
215. Lamont, B., Li, Y., Kwan, E., Brown, T. J., Gaisano, H., and **Drucker D. J.** Pancreatic GLP-1 receptor activation is sufficient for GLP-1R-dependent control of glucose homeostasis in mice J Clin Invest 2012;122(1):388–402
216. Lee, S-J., Lee, J., Li, K. K., Holland, D., Maughan, H., Guttman, D. S., Yusta, B., and **Drucker D. J.** Disruption of the murine *Glp2r* impairs Paneth cell function and increases susceptibility to small bowel enteritis Endocrinology 2012 153(3):1141-51
217. Yusta, B., Holland, D., Waschek, J., **Drucker, D. J.** Intestinotrophic Glucagon-Like Peptide-2 (GLP-2) Activates Intestinal Gene Expression and Growth Factor-Dependent Pathways Independent of the Vasoactive Intestinal Peptide Gene in Mice Endocrinology 2012 Jun;153(6):2623-32
218. Rieg, T., Gerasimova, M., Murray, F., Masuda, T., Tang, T., Rose, M., **Drucker, D.J.**, and Vallon, V. The natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice Am. J. Physiol. Renal 2012 Oct;303(7):F963-71
219. Burmeister M.A., Bracy D.P., James F.Y., Holt R.M., Ayala J., King E.M., Wasserman D.H., **Drucker D. J.** and Ayala J.E. Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor J Physiol. 2012 Oct 15;590(Pt 20):5245-55
220. Martin, C., Passilly-Degrace, P., Chevrot, M., Ancel, D., Sparks, S. M., **Drucker, D. J.**, and Besnard, P. Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity J Lipid Res 2012 Nov;53(11):2256-65
221. Lockie, S. H., Heppner, K. M., Chaudhary, N., Chabenne, J. R., Morgan, D. A., Veyrat-Durebex, C., Ananthakrishnan, G., Rohner-Jeanrenaud, F., **Drucker, D. J.**, DiMarchi, R., Rahmouni, K., Oldfield, B. J., Tschöp, M. H., Perez-Tilve, D. Direct control of Brown Adipose Tissue thermogenesis by Central Nervous System Glucagon-Like Peptide-1 receptor signaling Diabetes 2012 Nov;61(11):2753-62
222. Flock, G. B., Cao, X., Maziarz, M., and **Drucker D. J.** Activation of enteroendocrine membrane progesterone receptors promotes incretin secretion and improves glucose tolerance in mice Diabetes 2013 62:283-290

223. Fukami, A., Seino, Y., Ozaki, N., Yamamoto, M., Sugiyama, C., Sakamoto-Miura E., Himeno, T., Takagishi, Y., Tsunekawa, S., Ali, S., **Drucker, D.J.**, Murata, Y., Seino, Y., Oiso, Y., and Hayashi Y. Ectopic expression of GIP in pancreatic β -cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides Diabetes 2013 Feb;62(2):510-8
224. Longuet, C., Robledo, A.M., Dean, E.D., Dai, C., Ali, S., McGuinness, I., de Chavez, V., Vuguin, P.M., Charron, M.J., Powers, A.C., **Drucker D.J.** Liver-specific disruption of the murine glucagon receptor produces alpha-cell hyperplasia: evidence for a circulating alpha-cell growth factor Diabetes 2013 (4) 1196-1205
225. Panjwani, N., Mulvihill, E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao. X., Baggio, L. L., **Drucker, D. J.** GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male *ApoE*^{-/-} mice Endocrinology 2013 154: 127-139
226. Noyan-Ashraf M.H., Shikatani E.A., Schuiki I., Mukovozov I.M., Wu J., Li R.K., Volchuk A., Robinson L.A., Billia F., **Drucker D. J.**, Husain M. A glucagon-like peptide-1 analogue reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity Circulation 2013 Jan 1;127(1):74-85
227. Burmeister, M. A., Ayala, J. E., **Drucker D. J.**, Ayala, J. E. Central Glucagon-Like Peptide 1 Receptor (Glp1r)-Induced Anorexia Requires Glucose Metabolism-Mediated Suppression of AMPK and is Impaired by Central Fructose Am J Physiol Endocrinol Metab. 2013 Apr;304(7):E677-85
228. Wilson-Pérez, H. E., Chambers, A. P., Ryan, K. K., Li, B., Sandoval, D. A., Stoffers, D., **Drucker, D. J.**, Pérez-Tilve, D., Seeley, R. J. Vertical Sleeve Gastrectomy is Effective in Two Genetic Mouse Models of Glucagon-like Peptide-1 Receptor Deficiency Diabetes. 2013 Jul;62(7):2380-5
229. Kim, M., Platt, M., Shibasaki, T., Quaggin, S., Backx, P. H., Seino, S., Simpson, J., **Drucker, D. J.** GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure Nature Medicine 2013 19: 567-575
230. Mukharji, A., **Drucker, D. J.**, Charron, M. J., and Swoap, S. J. Oxyntomodulin increases intrinsic heart rate through the glucagon receptor Physiological Reports 2013 Oct;1(5):e00112.
231. Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., **Drucker, D. J.**, Seino, Y., Yamada, Y. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential Kidney International 2014 Mar;85(3):579-89.
232. Finan, F., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., Lockie, S. H., Smiley, D. L., Gelfanov, V., Yang, B., Hofmann, S., Bruemmer, D., **Drucker, D. J.**, Pfluger, P. T., Perez-Tilve, D., Gidda, J., Vignati, L., Zhang, L., Hauptman, J. B., Lau, M., Brecheisen, M., Uhles, S., Riboulet, W., Hainaut, E., Sebokova, E., Conde-Knape, K., Konkar, A., DiMarchi, R. D., Tschöp, M. H. Novel Unimolecular Dual-Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans Science Translational Medicine 2013 Vol. 5, Issue 209, p. 209ra151 *Sci. Transl. Med.* DOI: 10.1126/scitranslmed.3007218
233. Wichmann, A., Allahyar, A., Greiner, T. U., Plovier, H., Östergren Lundén, G., Larsson, T., **Drucker, D. J.**, Delzenne, N. M., Cani, P. D., Bäckhed, F. Microbial Modulation of Energy Availability in the Colon Regulates Intestinal Transit Cell Host and Microbe 2013 14(5)582-590
234. Nguyen, A., Thoai, Mandard, S., Dray, C., Deckert, V., Besnard, P., **Drucker, D. J.**, Lagrost, L., Grober, J. Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: Involvement of the glucagon-like peptide 1 (GLP1) pathway. Diabetes 2014 Feb;63(2):471-82
235. Mokadem, M., Zechner, J. F., Margolskee, R. F., **Drucker, D. J.**, Aguirre, V. Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency Molecular Metabolism 2013 Dec 11;3(2):191-201.

236. Ye, J., Hao, Z., Mumphrey, M. B., Townsend, R. L., Patterson, L. M., Stylopoulos, N., Münzberg, H. Morrison, C. D., **Drucker, D. J.**, Berthoud, H.-R. GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents *Am J Physiol* 2014 Mar;306(5):R352-62.
237. Johswich A, Longuet C, Pawling J, Abdel Rahman A, Ryczko M, **Drucker D. J.**, Dennis J. W. N-glycan Remodeling on Glucagon Receptor is an Effector of Nutrient-sensing by the Hexosamine Biosynthesis Pathway *J. Biol Chem* 2014 Jun 6;289(23):15927-15941.
238. Ussher, J. R., Baggio, L. L., Campbell, J. E., Mulvihill, E. E., Kim, M., Kabir, M. G., Cao, X., Baranek, J., Stoffers, D. A., Seeley, R. J., **Drucker, D. J.** Inactivation of the cardiomyocyte Glucagon-Like Peptide-1 Receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection *Molecular Metabolism* 3 (2014), 507-517
239. Moffett, R. C., Vsu, S., Thorens, B., **Drucker, D. J.**, Flatt, P. R. Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy *PLoS One*. 2014 Jun 13;9(6): e96863. doi: 10.1371/journal.pone.0096863
240. Koehler, J. A., Baggio, L. L., Cao, X., Abdulla, T., Campbell, J. E., Secher, T., Jelsing, J., Larsen, B., **Drucker, D. J.** Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis *Diabetes* 2015; 64:1046-1056
241. Lovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., **Drucker, D. J.** Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes *Diabetes Care* 2015 Jan;38(1):132-9.
242. Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., Campbell, J. E., Sandoval, D., Seeley, R. J., Bleicher, K., Uhles, S., Riboulet, W., Funk, F., Hertel, C., Belli, S., Sebkova, S., Conde-Knape, K., Konkar, A., **Drucker, D. J.**, Gelfanov, V., Pfluger, P. T., Müller, T. D., Perez-Tilve, D., DiMarchi, R. D., Tschöp, M. H. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents *Nature Med* (2015) Jan;21(1):27-36
243. Gagnon, J., Baggio, L. L., **Drucker, D. J.**, Brubaker, P. L. Ghrelin is a novel regulator of glucagon-like peptide-1 secretion *Diabetes* 2015 64(5):1513-21
244. Ali, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., **Drucker, D. J.** Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction *Molecular Metabolism* 2015(4)132-143.
245. Koehler, J. K., Baggio, L. L., Yusta, B., Longuet, C., Rowland, K. J., Cao, X., Holland, D., Brubaker, P. L., and **Drucker D. J.** GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring *Fgf7* *Cell Metabolism* 2015 21(3):379–391
246. Landgraf, D., Tsang, A. H., Leliavski, A., Koch, C.E., Barclay, J. L., **Drucker, D. J.**, Oster, H. Oxyntomodulin regulates resetting of the liver circadian clock by food *eLife* 2015;10.7554/eLife.06253
247. Takaia, S., Yasumatsub, K., Inouea, M., Iwataa, S., Yoshidaa, R., Shigemuraa, N., Yanagawac, Y., **Drucker, D. J.**, Margolskee, R. F., Ninomiya, Y. Glucagon-like peptide-1 is specifically involved in sweet taste transmission *FASEB J* 2015 Jun;29(6):2268-80
248. Harasta, A., Power, J., Jonquieres, G., Karl, T., **Drucker, D. J.** Housley, G., Schneider, M., and Klugmann, M. Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behaviour *Neuropsychopharmacology* 2015 Jul;40(8):1969-78.

249. Yusta, B., Baggio, L. L., Koehler, J. A., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A.A., Sherman, P. M., **Drucker, D. J.** GLP-1 receptor (GLP-1R) agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte (IEL) GLP-1R Diabetes 2015 64(11):2537–2549
250. Oropeza, D., Jouvett, N., Budry, L., Campbell, J. E., Bouyakdan, K., Lacombe, J., Perron, G., Bergeron, V., Neuman, J. C., Brar, H. K., Fenske, R. J., Meunier, C., Sczelecki, S., Kimple, M. E., **Drucker, D. J.**, Sreaton, R. A., Poitout, V., Ferron, M., Alquier, T., Estall, J. L. Phenotypic Characterization of MIP-CreERT1Lphi Mice With Transgene-Driven Islet Expression of Human Growth Hormone Diabetes 2015;64:3798–3807
251. Claussnitzer, M., Dankel, S. N., Kim, K.-H., Quon, G., Meuleman, W., Haugen, C., Glunk, V., Sousa, I. S., Beaudry, J. L., Puvion-Rand, V., Abdennur, N. A., Liu, J., Svensson, P.-A., Hsu, Y.-H., **Drucker, D. J.**, Mellgren, G., Hui, C.-C., Hauner, H., Kellis, M. FTO Obesity Variant Circuitry and Adipocyte Browning in Humans N Eng J Med. 2015 Sep 3;373(10):895-907
252. Campbell, J. E., Ussher, J. R., Mulvihill, E. E., Baggio, L. L., Kolic, J., Cao, X., Liu, Y., Lamont, B. J., Morii, T., Streutker, C., Tamarina, N., Philipson, L. H., Wrana, J. L., MacDonald, P. E., and **Drucker, D. J.** TCF1 links GIPR signaling to the control of beta cell function and survival Nature Medicine 2016 22(1)84–90
253. Mulvihill, E. E., Elodie M. Varin, E. M., Ussher, J. R., Campbell, J. E., Bang, K. W. A., Abdullah, T., Baggio, L. L., **Drucker, D. J.** Inhibition of Dipeptidyl Peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice Diabetes 2016 65(3):742-754
254. Arora, T., Wegmann, U., Bobhate, A., Lee, Y.S., Greiner, T.U., **Drucker, D.J.**, Narbad, A., and Bäckhed, F. Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice. Molecular Metabolism. 2016 Jun 22;5(8):725-30
255. Sánchez-Garrido, M.A., Habegger, K.M., Clemmensen, C., Holleman, C., Müller, T.D., Perez-Tilve, D., Li, P., Agrawal, A.S., Finan, B., **Drucker, D.J.**, Tschöp, M.H., DiMarchi, R.D., and Kharitonov, A. Fibroblast Activation Protein (FAP) as a Novel Metabolic Target Molecular Metabolism 2016. Jul 16;5(10):1015-24
256. Takashima, S., Fujita, H., Fujishima, H., Shimizu, T., Sato, T., Morii, T., Tsukiyama, K., Narita, T., Takahashi, T., **Drucker, D. J.**, Seino, Y., Yamada, Y. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy Kidney International 2016 Oct;90(4):783-96
257. Lynch, L., Hogan, A. E., Duquette, D., Lester, C., Banks, A., LeClair, K., Cohen, D. E., Ghosh, A., Lu, B., Corrigan, M., Stevanovic, D., Maratos-Flier, E., **Drucker, D. J.**, O'Shea, D., Brenner, M. iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy Cell Metabolism (2016), Sep 13;24(3):510-9
258. Mulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., Bang, K. W. A., Ayala, J. E., **Drucker D. J.** Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis Cell Metabolism 2017 Jan 10;25(1):152-165
259. Burmeister, M.A., Ayala, J.E., Smouse, H., Landivar-Rocha, A., Brown, J. D., **Drucker, D. J.**, Stoffers, D. A., Sandoval, D. A., Seeley, R. J., Ayala, J. E. The Hypothalamic Glucagon-Like Peptide-1 (GLP-1) Receptor (GLP-1R) is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice Diabetes 2017 Feb;66(2):372-384.
260. Lee, K., Koehler, J., Yusta, B., Bahrami, J., Matthews, D., Rafii, M., Pencharz, P. B., **Drucker D. J.** Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport Molecular Metabolism 6 (2017) 245-255

261. Chambers, A. P., Sorrell, J., Haller, A., Roelofs, K., Hutch, C., Kim, K-S., Gutierrez-Aguilar, R., Li, B., **Drucker, D. J.**, D'Alessio, D. A., Seeley, R. J. Sandoval, D. A. The role of pancreatic preproglucagon in glucose homeostasis in mice *Cell Metabolism* 2017 Apr 4;25(4):927-934
262. Panaro, B. L., Flock, G. B., Campbell, J. E., Beaudry, J. L., Cao, X., **Drucker, D. J.** β -cell inactivation of *Gpr119* unmasks incretin-dependence of GPR119-mediated glucoregulation *Diabetes* 2017 Jun; 66 (6): 1626-1635
263. Yusta, B., Matthews, D., Flock, G. B., Ussher, J.R., Lavoie, B., Mawe, G. M., **Drucker, D. J.** Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway *Molecular Metabolism* 2017 6(6):503–511
264. Wismann, P., Barkholt, P., Secher, T., Vrang, N., Hansen, H. B., Jeppesen, P. B., Baggio, L. L., Koehler, J. A., **Drucker, D. J.**, Sandoval D. A., Jelsing, J. The endogenous preproglucagon system is not essential for gut growth homeostasis in mice *Molecular Metabolism* 2017 Apr 27;6(7):681-692
265. Lovshin, J.A., Rajasekeran, H., Lytvyn, Y., Lovblom, L.E., Khan, S., Alemu, R., Locke, A., Lai, V., He, H., Hittle, L., Wang, W., **Drucker, D. J.**, Cherney, D.Z.I. Dipeptidyl Peptidase-4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1 α ¹⁻⁶⁷ in Patients With Type 2 Diabetes *Diabetes Care* 2017;40 (8): 1073-1081
266. Baggio, L.L., Ussher, J.E., McLean, B.A., Cao, X., Kabir M.G., Mulvihill, E.E., Mighiu, A., Zhang, H., Ludwig, A., Seeley, R.J., Heximer, S.P., **Drucker, D.J.** The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice *Molecular Metabolism* 2017: 6(11) 1339-1349
267. Lebrun, L.J., Kaatje Lenaerts, J., Kiers, D., Pais de Barros, J.-P., Le Guern, N., Plesnik, J., Thomas, C., Bourgeois, T., Dejong, C.H.C., Kox, M., Hundscheid, I.H.R., Khan, N.A., Mandard, S., Deckert, V., Pickkers, P., **Drucker, D. J.**, Lagrost, L., Grober, J. Enteroendocrine cells sense LPS after gut barrier injury to enhance GLP-1 secretion *Cell Reports* Oct 31 2017; 21(5) 1160-1168
268. Ussher, J. R., Campbell, J. E., Mulvihill, E. E., Baggio, L. L., Bates, H. E., McLean, B. A., Gopal, K., Capozzi, M., Yusta, B., Cao, X., Ali, S., Kim, M., Kabir, M. G., Seino, Y., Suzuki, J., **Drucker, D. J.** Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes Following Experimental Myocardial Infarction *Cell Metabolism* 2018 Feb 6;27(2):450-460
269. Iwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., Hayakawa, M., Masuda, C., Okada, T., Hara, H., **Drucker, D. J.**, Yamada, Y., Tokuda, M., Yada, T. GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose *Nature Communications* 9, 113(2018) doi:10.1038/s41467-017-02488-y
270. Jansson, J.-O., Palsdottir, V., Hägg, D. A., Schélel, E., Dickson, S. L., Anesten, F., Bake, T., Montelius, M., Bellman, J., Johansson, M. E., Cone, R. D., **Drucker, D. J.**, Wu, J., Aleksic, B., Törnqvist, A. E., Sjögren, K., Gustafsson, J.-A., Windahl, S. H., Ohlsson, C. A body weight homeostat that regulates fat mass independently of leptin in rats and mice *PNAS* 2018 115(2):427-432
271. Remm, F., Krankel, N., Lener, D., **Drucker, D. J.**, Sopper, S., Brenner, C. Sitagliptin accelerates endothelial regeneration after vascular injury independent from GLP1 receptor signaling *Stem Cells International*, 2018, 5284963
272. Baggio, L.L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T.P. Margulies, K. B., **Drucker, D. J.** GLP-1 receptor expression within the human heart *Endocrinology* (2018), April 1;159(4):1570-1584
273. Kim, T., Nason, S., Holleman, C., Pepin, M., Wende, A., Steele, C., Young, M., Barnes, S., **Drucker, D. J.**, DiMarchi, R., Perez-Tilve, D., Tschoep, M., & Habegger, K. M. Glucagon-receptor signaling regulates energy metabolism via hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21 *Diabetes*. 2018 Sep;67(9):1773-1782.

274. Patel, A., Yusta, B., Matthews, D., Charron, M.J., Seeley, R. J., and **Drucker D. J.** GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in *Gcgr*^{-/-} mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomy *Mol Metabolism* 2018 Oct;16:45-54
275. Kim T, Loyd C, Holleman C, Arble D.M, Ottaway N, Chabenne J, Sandoval D, **Drucker D.J.**, DiMarchi R.D, Perez-Tilve D, & Habegger K.M. Glucagon-receptor signaling enhances insulin sensitivity in rodents. *Diabetes*. 2018 Nov;67(11):2157-2166
276. Varin, E. M., Mulvihill, E. E., Beaudry, J. L., Pujadas, G., Fuchs, S., Tanti, J.-F., Fazio, S., Kaur, K., Cao, X., Baggio, L. L., Matthews, D., Campbell, J. E., **Drucker, D. J.** Circulating levels of soluble dipeptidyl peptidase-4 are dissociated from inflammation and induced by enzymatic DPP4 inhibition *Cell Metabolism* 2019; 29 (2) 320-334.
277. Svendsen, B., Larsen, O., Gabe, M. B. N., Christiansen, C. B., Rosenkilde, M. M., **Drucker, D. J.**, Holst, J. J., Insulin secretion depends on intraislet glucagon signaling *Cell Reports* 2018 25(5)1127-1134.
278. Panaro, B. L., Coppage, A. L., Beaudry, J. L., Varin, E. M., Kaur, K., . Lai, J. H., Wu, W., Liu, Y., Bachovchin, W. W., **Drucker, D. J.** Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice *Molecular Metabolism* 2019 (1) 58-69
279. Mantelmacher, F.D., Zvibel, I., Cohen, K., Epshtein, A., Pasmanik-Chor, M., Vogl, T., Kuperman, Y., Weiss, S., **Drucker, D. J.**, Varol, C., and Fishman, S. GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9 *Nature Metabolism* 2019 January (1) 58–69
280. He, S., Kahles, F., Rattik, S., Nairz, M., McAlpine, C. S., Anzai, A., Selgrade, D., Fenn, A.M., Chan, C.T., Mindur, J. E., Valet, C., Poller, W., Hall, L., Rotllan, N., Iwamoto, Y., Wojtkiewicz, G.R., Weissleder, R., Libby, P., Fernández-Hernando, C., **Drucker, D. J.**, Nahrendorf, M., Swirski, F. K. Gut intraepithelial T cells calibrate dietary metabolism and accelerate cardiovascular disease *Nature* 2019 566, 115–119
281. Beaudry, J.L., Kaur, K., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Stern, J. H., Campbell, J. E., Scherer, P. E., **Drucker, D. J.** The Brown Adipose Tissue Glucagon Receptor is Functional But Not Essential for Control of Energy Homeostasis in Mice *Molecular Metabolism* 2019 Apr;22:37-48
282. Varin E.M., Mulvihill E.E., Baggio L.L., Koehler J.A., Cao X., Seeley R.J., **Drucker D.J.** Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action *Cell Rep*. 2019 Jun 11;27(11):3371-3384.e3
283. Yusta, B., Matthews D, Koehler J. A, Pujadas G, Kaur K, **Drucker D. J.** Localization of Glucagon-like Peptide-2 Receptor Expression in the Mouse *Endocrinology* 2019 Aug 1;160(8):1950-1963
284. Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Bates, H. E., Campbell, J. E., **Drucker, D. J.** Physiological roles of the GIP receptor in murine brown adipose tissue *Molecular Metabolism* 2019 Oct 28:14-25. <https://www.sciencedirect.com/science/article/pii/S2212877819306179>
285. Findeisen, M., Allen, T. L., Henstridge, D. C., Kammoun, H., Brandon, A. E., , Baggio, L. L., Pal, M., Cron, L., Estevez, E., Yang, C., Kowalski, G. M., O'Reilly, L., Egan, C., Sun, E., May Thai, L., Krippner, G., Adams, T. E., Lee, R. S. Gröttinger, J., Risis, S., Kraakman, M. J., Mellet, N. A., Young, R. L., Cowley, M. A., Bruce, C. R., Meikle, P. J., Baldock, P. A., Biden, T. J., Cooney, G. J., , Keating, D. J., **Drucker, D. J.**, Rose-John S., Febbraio, M. A. Treatment of type 2 diabetes with the designer cytokine IC7Fc *Nature* 2019 574: 63-68
286. Song, Y., Koehler, J. A., Baggio, L.L., Powers, A. C, Sandoval, D.A., **Drucker D. J.** Gut proglucagon-derived peptides are essential for regulating glucose homeostasis in mice *Cell Met* 2019 30:976-986

287. Miyamoto, J., Igarashi, M., Watanabe, K., Karaki, S-I., Mukouyama, H., Kishino, S., Li, X., Ichimura, A., Irie, J., Sugimoto, J., Mizutani, T., Sugawara, T., Miki, T., Ogawa, J., **Drucker, D. J.** Arita, M., Itoh, H., and Kimura, H. Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids *Nature Communications* 2019 10(1)4007 10.1038/s41467-019-11978-0
288. Deshmukh, A.S., Peijs L., Beaudry, J. L., Jespersen, N. Z., Nielsen, C. H., Ma, T., Brunner, A. D., Larsen, T. J., Bayarri-Olmos, R., Prabhakar, B. S., Helgstrand, C., Severinsen, M. C. K., Holst, B., Kjær, A., Tang-Christensen, M., Sanfridson, A., Garred, P., Privé, G. G., Pedersen, B. K., Gerhart-Hines, Z., Nielsen, S., **Drucker, D. J.**, Mann, M., Scheele, C. Proteomics-based comparative mapping of the secretomes of human brown and white adipocytes reveals EPDR1 as a novel batokine *Cell Metabolism* 2019 30 (5), 963-975.e7
289. Helmstädter, J., Frenis, K., Filippou, K., Grill, A., Dib, M., Kalinovic, S., Pawelke, F., Kus, K., Kröller-Schön, S., Oelze, M., Chlopicki, S., Schuppan, D., Wenzel P., Ruf, W., **Drucker, D. J.**, Münzel, T., Daiber A., Steven, S. Cardiovascular protection by liraglutide in mice with experimental arterial hypertension is mediated by the endothelial GLP-1 receptor *Arterioscler Thromb Vasc Biol.* 2020; Jan;40(1):145-158
290. Filippidou, F. M., Kirsch, A. H., Thelen¹ M., Kétszeri, M., Artinger, K., Aringer, I., Schabhüttl, C., Mooslechner, A. A., Frauscher, B., Pollheimer, M., Niedrist, T., Meinitzer, A., **Drucker, D. J.**, Pieber, T. R., Eller P., Rosenkranz, A.R., Heinemann, A., Eller K. Glucagon like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T cell proliferation *American J Pathology* 2020 190(2):400-411
291. Lund, M.L, Sorrentino, G, Egerod, K.L, Kroone, C, Mortensen, B, Knop, F.K, Reimann, F, Gribble, F.M, **Drucker, D. J.**, de Koning, E.J.P, Schoonjans, K., Bäckhed, F., Schwartz, T. W., and Petersen, N. L-Cell Differentiation Is Induced by Bile Acids Through GPBAR1 and Paracrine GLP-1 and Serotonin Signaling. *Diabetes* 2020 Apr;69(4):614-623
292. Fuchs S, Yusta B, Baggio L. L, Varin E. M, Matthews D, **Drucker D. J.** Loss of *Glp2r* signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice *JCI Insight.* 2020 April 23, 5 (8). pii: 136907. doi: 10.1172/jci.insight.13690
293. Panaro, B.L., Yusta, B., Matthews, D., Koehler, J.A., Song, Y., Sandoval, D.A., **Drucker D.J.** Intestine-selective reduction of *Gcg* expression reveals the importance of the distal gut for GLP-1 secretion *Molecular Metabolism* 2020 Jul;37:100990
294. Pujadas, G., Varin E.M., Baggio, L.L. Mulvihill, E.E., Bang, K.W.A., Koehler, J.A., Matthews, D., **Drucker D.J.** The gut hormone receptor GIPR links energy availability to control of hematopoiesis *Molecular Metabolism* 2020 Sept (39) 101008 doi.org/10.1016/j.molmet.2020.101008
295. Baggio, L. L., Varin, E. M., Koehler J. A., Cao, X., Lokhnygina, Y., Stevens, S. R., Holman, R. R., **Drucker. D. J.** Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. *Nature Communications* 2020 Jul 28;11(1):3766.
296. Varin, E. M., Hanson, A.A., Beaudry, J. L., Nguyen, M.-A., Cao, X., Baggio, L. L., Mulvihill, E. E., **Drucker, D. J.**, Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans *JCI Insight* 2020 Aug 20;5(16):140418.
297. Sato, S., Shimizu, T., Fujita, H., Imai, Y., **Drucker, D. J.**, Seino, Y., Yamada, Y. GLP-1 receptor signaling differentially modifies the outcomes of sterile vs. viral pulmonary inflammation in male mice *Endocrinology* 2020 Dec 1;161(12):bqaa201.
298. Zhang Q., Delessa C.T., Augustin R., Bakhti, M., Colldén, G., **Drucker, D. J.**, Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., Herzig, S., Hofmann, S., Holleman, C. L., Jastroch, M., Keipert, S., Kleinert, M., Knerr, P. J. Kulaj, K., Legutko, B., Lickert, H., Liu, X., Luippold, G., Lutter, D., Malogajski, E., Medina, M. T., Mowery, S. A., Blutke, A., Perez-Tilve, D., Salinno, C., Sehrer, L., DiMarchi, R. D., Tschöp, M. H., Stemmer, K., Finan, B., Wolfrum,

- C., Müller, T. D., (2021) The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. *Cell Metabolism* 33 (33), 833–844
299. GIPR signaling in immune cells maintains metabolically beneficial type 2 immune responses in the white fat from obese mice Efimova, I., Steinberg, I., Zvibel, I., Neumann, A., Mantelmacher, D.F., **Drucker, D. J.**, Sigal Fishman, S., Varol, C. *Frontiers Immunology* 2021 25;12:643144 <https://doi.org/10.3389/fimmu.2021.643144>
300. Kaur K.D., Wong CK, Baggio LL, Beaudry JL, Fuchs S, Panaro BL, Matthews D, Cao X, **Drucker D.J.** TCF7 is not essential for glucose homeostasis in mice *Mol Metab.* 2021 Mar 16:101213. doi: 10.1016/j.molmet.2021.101213
301. Heiss, C. N., Mannerås-Holm, L., Lee, Y. S., Serrano Lobo, J., Anna Håkansson, Seeley, R. J., **Drucker, D. J.**, Bäckhed, F., Olofsson, L. E., The gut microbiota regulates hypothalamic inflammation and leptin sensitivity in Western diet-fed mice via a GLP-1 receptor-dependent mechanism *Cell Reports* 2021 May 25;35(8):109163. doi: 10.1016/j.celrep.2021.109163
302. Overgaard, R.V., Hertz, C. L., Ingwersen, S. H., Navarria, A., **Drucker, D.J.** Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes *Cell Reports Medicine* 2021 (2) 100387 <https://doi.org/10.1016/j.xcrm.2021.100387>
303. McLean, B. A., Wong, C.K., Kaur, K.D., Seeley, R.J., **Drucker, D. J.** Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic vs. hepatic actions of semaglutide *JCI Insight* 2021 6(22) Oct 21:e153732.
304. Campbell, J. E. Beaudry JL, Svendsen B, Baggio L.L., Gordon AN, Ussher JR, Wong CK, Gribble FM, D'Alessio DA, Reimann F, **Drucker, D.J.** The GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue. *Diabetes.* 2022 71(5):1115-1127 doi: 10.2337/db21-1166
305. Chen M.E., Naeini S.M., Srikrishnaraj A, **Drucker D.J.**, Fesler Z., Brubaker P.L. Glucagon-like peptide-2 stimulates S-phase entry of intestinal Lgr5+ stem cells *Cell Mol Gastroenterol Hepatol.* 2022 Feb 23:S2352-345X(22)00038-8.
306. Quarta C., Stemmer K., Novikoff A., Yang B., Klingelhuber F., Harger A., Bakhti M., Bastidas-Ponce A., Baugé E., Campbell J.E., Capozzi M., Clemmensen C., Collden G., Cota P., Douros J, **Drucker D.J.**, DuBois B, Feuchtinger A, Garcia-Caceres C., Grandl G., Hennuyer N., Herzig S., Hofmann S.M., Knerr P., Kulaj K., Lalloyer E., Lickert H., Liskiewicz A., Liskiewicz D., Maity G., Perez-Tilve D., Prakash S., Sanchez Garrido M., Zhang Q., Staels B., Krahmer N., DiMarchi R.D., Tschöp M.H., Finan B., Müller T.D. GLP-1-mediated delivery of the PPAR α/γ dual-agonist Tesaglitazar improves obesity and glucose metabolism in mice *Nature Metabolism* 2022 Aug;4(8):1071-1083 <https://doi.org/10.1038/s42255-022-00617-6>
307. Wong, C.K., Yusta, B., Koehler, J. A., Baggio, L.L., McLean, B.A., Matthews, D., Seeley, R.J., **Drucker D.J.** Divergent roles for the gut intraepithelial lymphocyte GLP-1 receptor in control of metabolism, microbiota, and T cell-induced inflammation *Cell Metabolism* 2022 Oct 4;34(10):1514-1531 <https://doi.org/10.1016/j.cmet.2022.08.003>
308. Pujadas, G., Baggio, L.L., Kaur, K.D., McLean, B.A., Cao, X., **Drucker, D. J.** Genetic disruption of the *Gipr* in *Apoe*^{-/-} mice promotes atherosclerosis *Molecular Metabolism* 2022 Nov (65) 101586 doi.org/10.1016/j.molmet.2022.101586
309. Zimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., **Drucker, D. J.**, Klein, H., Santhanam, R., Hamprecht, D., Neubauer, H., Augustin R. BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy *Molecular Metabolism* 2022 doi.org/10.1016/j.molmet.2022.101633

310. McLean, B. A., Wong, C. K. Kabir, M. G., **Drucker D. J.** Glucagon-Like Peptide-1 Receptor Tie2⁺ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction *Molecular Metabolism* 2022 Dec;66:101641. doi: 10.1016/j.molmet.2022.101641
311. Castle A.R., Kang S.G., Eskandari-Sedighi G., Wohlgemuth S., Nguyen M.A., **Drucker D. J.**, Mulvihill E.E., Westaway D. Beta-endoproteolysis of the cellular prion protein by dipeptidyl peptidase-4 and fibroblast activation protein. 2023 Jan 3;120(1):e2209815120. doi: 10.1073/pnas.2209815120
312. Le, T.D.V., Fathi, P., Watters, A.B., Ellis, B.J., Bozadjieva-Kramer, N., Perez, M.B., Sullivan, A.I., Rose, J.P., Baggio, L.L., Koehler J, Brown J.L., Bales M.B, Nwaba K.G., Campbell J.E., **Drucker D.J.**, Potthoff MJ, Seeley RJ, Ayala JE Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate Diets *Molecular Metabolism* 2023 Jun;72:101718. doi: 10.1016/j.molmet.2023.101718
313. Ochiai, K., Muto, A., Seok, B.S., Doi, Y., Iwasaki, Y., Okamatsu-Ogura, Y., **Drucker, D. J.**, Hira, T. Glucagon-like peptide-1 is involved in the thermic effects of dietary proteins in male rodents *Endocrinology* 2023 Apr 17;164(6):bqad068. doi: 10.1210/endocr/bqad068
314. Sourris K.C., Ding Y, Maxwell S.S., Al-sharea A, Kantharidis P, Mohan M, Rosado C.J., Penfold S.A., Haase C, Xu Y, Forbes J.M., Crawford S, Ramm G, Harcourt B.E., Jandeleit-Dahm K, Advani A, Murphy A.J., Timmermann D.B., Karihaloo A, Knudsen L.B., El-Osta A, **Drucker D.J.**, Cooper M.E., Coughlan M.T. GLP-1 receptor signaling modifies the extent of diabetic kidney disease through dampening RAGE-induced inflammation. *Kidney International* 2024 Jan;105(1):132-149. doi: 10.1016/j.kint.2023.09.029
315. Wong, C.K., Maclean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. K., **Drucker, D. J.** Central glucagon-like peptide 1 receptor activation inhibits Toll like receptor -induced inflammation *Cell Metabolism* 2024 36(1):130-143 <https://doi.org/10.1016/j.cmet.2023.11.009>
316. Wang, M-Y., Zhang, Z., Zhao, S., Onodera, T., Sun, X., Zhu, Q., Li, C., Li, N., Chen, S., Marciano, D.K., Gordillo, R., **Drucker, D.J.**, Scherer, P. E. Down-regulation of kidney glucagon receptor, essential for normal renal function and systemic homeostasis, contributes to the development of chronic kidney disease *Cell Metabolism* 2024 (36)1: 575-597 <https://doi.org/10.1016/j.cmet.2023.12.024>
317. Akindehin S, Liskiewicz A, Liskiewicz D, Bernecker M, Garcia-Caceres C, **Drucker D.J.**, Finan B, Grandl G, Gutgesell R, Hofmann S.M, Khalil A, Liu X, Cota P, Bakhti M, Czarnecki O, Bastidas-Ponce A, Lickert H, Kang L, Maity G, Novikoff A, Parlee S, Pathak E, Schriever S.C, Sterr M, Ussar S, Zhang Q, DiMarchi R, Tschöp M.H, Pfluger P.T, Douros J.D, Müller T.D. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice *Mol Metab.* 2024 Mar 14:101915. doi: 10.1016/j.molmet.2024.101915
318. Greiner T.U, Koh A, Peris E, Bergentall M, Johansson M.E.V, Hansson G.C, **Drucker D.J.**, Bäckhed F. GLP-1R signaling modulates colonic energy metabolism, goblet cell number and survival in the absence of gut microbiota *Mol Metab.* 2024 Mar 21:101924. doi: 10.1016/j.molmet.2024.101924
319. Suba, K., Y Patel, Y., Martin-Alonso, A., Roberts, A., Hansen, B., Norton, M., Shrewsbury, J., Kwok, R., Kalogianni, V., Chen, S., Liu, S., Rutter, G.A., Jones, B., Minnion, J., Owen, B., Distaso, W., **Drucker, D.J.**, Tan, T.M.M., Bloom S.R., Murphy, K.G., V Salem, V. Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homeostasis *Mol Metabolism* 2024 Apr 26:85:101947 <https://doi.org/10.1016/j.molmet.2024.101947>
320. Gao C, Xiong Z, Liu Y, Wang M, Wang M, Liu T, Liu J, Ren S, Cao N, Yan H, **Drucker D.J.**, Rau C.D., Yokota T, Huang J, Wang Y Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction *Circ Res.* 2024 Aug 16;135(5):614-628. doi: 10.1161/CIRCRESAHA.124.324706.

321. Forny Germano, L., Koehler, J.A., Baggio, L.L. Rittig, N., Wong, C.K., Cui, F., Cao, X., Matthews, D., **Drucker, D.J.** The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice *Molecular Metabolism* 2024 doi: 10.1016/j.molmet.2024.102019
322. Ray P, Moggridge J.A, Weisman A, Tadrous M, **Drucker D.J**, Perkins BA, Fralick M. Glucagon-Like Peptide 1 Receptor Agonist Use in Hospital: A Multicentre Observational Study *Can J Diabetes* 2024 Oct 30:S1499-2671(24)00376-9.
323. Toki S, Abney M, Zhang J, Rusznak M, Warren CM, Newcomb DC, Cahill K.N, **Drucker D.J**, Niswender KD, Peebles R.S Jr.Endogenous Glucagon-Like Peptide-1 Receptor and Glucose-Dependent Insulinotropic Polypeptide Receptor Signaling Inhibits Aeroallergen-Induced Innate Airway Inflammation Allergy. 2024 Nov 19. doi: 10.1111/all.16402
324. Roell W, Coskun T, Kim T, O'Farrell L, Martin J.A, Nason S, Hernandez-Alamillo J, Dhantu S, Drucker **D.J**, Sloop K.W., Steele J.P., Alsina-Fernandez J, Habegger K. M. Characterization of LY3324954 a long-acting glucagon-receptor agonist *Mol Met* 2025 2025 Jan;91:102073. doi: 10.1016/j.molmet.2024.102073
325. Wean J, Kowalsky A.H, Laker R, Will S, **Drucker D.J**, Rhodes C.J, Seeley R.J Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss *Mol Met* 2024 Nov 26:102074.doi: 10.1016/j.molmet.2024.102074
326. Xu Y, Michalowski C.B., Koehler J, Darwish T, Guccio N., Alcaino C, Domingues I., Zhang. W., Marotti V., Van Hul M., Paone P., Koutsoviti M., Boyd B.J., **Drucker D.J.**, Cani P.D., Reimann F., Gribble F.M., Beloqui A. Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion *Sci Adv* 2024 Dec 13;10(50):eadq9909. doi: 10.1126/sciadv.adq9909.
327. Hammoud, R., Kaur, K.D, Koehler, J.A., Baggio, L.L., Wong, C.K., Advani, K.E., Yusta, B., Efimova, I., Gribble, F., Reimann, F., Fishman, S., Varol, C., **Drucker, D.J.** 2023 Glucose-dependent Insulinotropic Polypeptide Receptor Signaling Alleviates Gut Inflammation in Mice *JCI Insight* 10.1172/jci.insight.174825
328. Liu, C.M., Killion , E.A., Hammoud, R., Lu, S-C., Komorowski, R., Liu, T., Kanke, M., Thomas, V.A., Cook, K., Sivits Jr.,G.N., Ben,A.B., Atangan, L.I., Hussien, R., Tang, A., Shkumatov, A., Li , C-M., **Drucker, D.J.**, & Véniant, M.M. GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice *Nature Metabolism* 2025 <https://doi.org/10.1038/s42255-025-01295-w>
329. Yusta, B., Wong, C.K., Matthews, D., Koehler, J.A., Baggio, L.L. Bang, K.W.A., **Drucker, D.J.** GLP-1R signaling does not modify the severity of experimental graft versus host disease *Molecular Metabolism* 2025 <https://doi.org/10.1016/j.molmet.2025.102235>
330. Wong, C.K., Yusta, B., Tong, J., Hodson, D., **Drucker, D.J.** Reassessment of antibody-based detection of the murine T cell GLP-1 receptor *Cell Metabolism* 37(9) 1783–1788 2025 <https://doi.org/10.1016/j.cmet.2025.06.012>

Invited Reviews and Editorials

1. **Drucker D. J.**, Burrow, G.N. Hypothyroidism and heart disease. *Nuevos Archivos De Le Facultad de Medicina* 1983 41:451-452(Editorial)
2. **Drucker D. J.** Glucagon and the glucagon-like peptides. *Pancreas* 1990 5:484-488
3. **Drucker D. J.** Parathyroid hormone-like peptide. *Endocrine Pathology* 1991 2:4-11
4. Campos, R.V. and **Drucker D. J.** Transgenic mice and the pathophysiology of endocrine systems. *Endocrine Pathology* 1992 3:111-115
5. **Drucker D.J.** Molecular pathophysiology of glucagon-SV 40 T antigen transgenic mice. *Am J. Physiol* 1994 267:E629-E635
6. **Drucker D. J.** Intestinal growth factors. *Am. J. Physiol.* 1997 273:G3-G6
7. **Drucker D.J.** The glucagon-like peptides. *Diabetes* 1998 47:159-169
8. **Drucker D. J.** Glucagon-like peptide 2 1999 *Trends in Endocrinology and Metabolism* 10:153-156
9. **Drucker, D. J.**, Boushey R. P., Wang F., Hill, M. E., Brubaker P. L., Yusta B. Biologic properties and therapeutic potential of glucagon-like peptide-2 1999 *J Parenter Enteral Nutr* 23:S98-100
10. Lovshin, J., **Drucker, D. J.** Synthesis, secretion and biological actions of the glucagon-like peptides *Pediatric Diabetes* 2000:1: 49-57
11. **Drucker, D. J.** The glucagon-like peptides. *Endocrinology* 2001 142: 521-527
12. **Drucker, D. J.** Glucagon-like peptide-2. *J. Clin. Endocrinol. Metab.* 2001 86(4):1759-64.
13. **Drucker, D. J.** Development of Glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes *Current Pharmaceutical Design* 2001 7: 1399-1412
14. **Drucker, D. J.** Biological actions and therapeutic potential of the glucagon-like peptides. *Gastroenterology*. 2002 Feb;122(2):531-44.
15. **Drucker, D. J.** Gut adaptation and the glucagon-like peptides. *Gut*. 2002 Mar;50(3):428-35
16. Brubaker, P.L., and **Drucker, D. J.** Structure-Function of the Glucagon Receptor Family of G Protein Coupled Receptors: The Glucagon, GIP, GLP-1 and GLP-2 receptors. *Receptors and Ion Channels* 2002 8:179-188
17. **Drucker, D. J.** Therapeutic Potential of Dipeptidyl Peptidase-IV Inhibitors for the Treatment of Type 2 Diabetes. *Expert Opinion on Investigational Drugs* 2003 Jan;12(1):87-100
18. **Drucker, D. J.** Glucagon-like peptides: Regulators of cell proliferation and apoptosis *Mol Endocrinol* 2003 17(2):161-171
19. Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., and **Drucker, D. J.** International Union of Pharmacology. XXXV. The Glucagon Receptor Family. *Pharmacol Rev* 2003 55:167-194.

20. **Drucker, D. J.** Enhancing incretin action for the treatment of type 2 diabetes *Diabetes Care* 2003 26: 2929-2940
21. Estall, J. L., **Drucker, D. J.**, Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling. *J Nutr.* 2003 Nov;133(11):3708-11
22. **Drucker, D. J.** Glucagon-like peptide-1 (GLP-1) and the islet β cell: Augmentation of cell proliferation and inhibition of apoptosis *Endocrinology* 2003 Dec;144(12):5145-8
23. Brubaker, P. L. and **Drucker, D. J.** Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system *Endocrinology* 2004 Jun;145(6):2653-9
24. Baggio, L. L., and **Drucker, D. J.** Glucagon-like peptide-1 and glucagon-like peptide-2. *Best Pract Res Clin Endocrinol Metab.* 2004 Dec;18(4):531-554
25. Hansotia, T., and **Drucker, D. J.** GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice *Reg Peptides* 2005 Jun 15;128(2):125-34.
26. Estall, J. L. **Drucker, D. J.** Tales beyond the Crypt: Glucagon-Like Peptide-2 and Cytoprotection in the Intestinal Mucosa. *Endocrinology.* 2005 Jan;146(1):19-21.
27. Shin, E. D., **Drucker, D. J.**, and Brubaker, P. L. Glucagon-like peptide-2: an update 2 *Curr Opin Endocrinol Diabetes* 2005 12:63-71
28. Sinclair, E. M., **Drucker, D. J.**, Glucagon-like peptide-1 receptor agonists and Dipeptidyl Peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes *Current Opinion in Endocrinology and Metabolism* vol 12 April 2005 146-151
29. Sinclair, E. M. and **Drucker, D. J.** Proglucagon-derived peptides: Mechanism of action and therapeutic potential *Physiology* 2005 20: 357-365
30. **Drucker, D. J.** Biological actions and therapeutic potential of the proglucagon-derived peptides *Nature Clinical Practice Endocrinology & Metabolism* (2005) 1, 22-31
31. Riddle, M. C. and **Drucker, D. J.** Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 *Diabetes Care* 2006 29: 435-449
32. **Drucker D. J.** The biology of incretin hormones *Cell Metabolism* 2006 Mar;3(3):153-65.
33. **Drucker, D. J.** Enhancing the action of incretin hormones: a new whey forward? *Endocrinology.* 2006 Jul;147(7):3171-2.
34. Estall, J. L., and **Drucker, D. J.** Glucagon and glucagon-like peptide receptors as drug targets. *Curr Pharm Des.* 2006;12(14):1731-50.
35. Baggio, L.L., and Drucker, D. J. Therapeutic approaches to preserve islet mass in type 2 diabetes *Annual Review of Medicine* 2006 57:265-281
36. **Drucker, D. J.** and Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes *Lancet* 2006 368: 1696-705
37. **Drucker D. J.** The role of gut hormones in glucose homeostasis. *J. Clin. Invest.* 2007 117: 24-32
38. **Drucker D.J.**, Easley C, Kirkpatrick P. Sitagliptin. *Nat Rev Drug Discov* 2007; 6:109-10.

39. Baggio, L. L. and **Drucker D.J.** Biology of Incretins: GLP-1 and GIP *Gastroenterology* 2007 132:2131-2157
40. Hadjiyanni, I., **Drucker D. J.** Glucagon-like peptide-1 and type 1 diabetes: NOD ready for prime time? *Endocrinology* 2007;148(11):5133-5
41. Schuit, F., and **Drucker, D. J.** Beta cell replication by loosening the brakes of glucagon-like peptide-1 receptor signaling *Diabetes* 2008 Mar;57(3):529-31
42. Goldberg, R. M., Holman, R., and **Drucker, D. J.** Treatment of type 2 diabetes *New Eng J Med* 2008 358: 293-297
43. Retnakaran, R., and **Drucker, D. J.** Intensive insulin therapy in newly diagnosed type 2 diabetes *Lancet* 2008 371:1725-1726
44. Ali, S., and **Drucker D. J.** Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes *Am J Physiol Endocrinol Metab* Mar 2009; 296:E415-E421
45. Lovshin, J. A. and **Drucker D. J.** Incretin-based therapies for type 2 diabetes mellitus *Nature Reviews Endocrinology* 2009 (5) 262-269
46. Martin, B., Dotson, C. D., Shin, Y. K., Ji, S., **Drucker, D. J.**, Maudsley, S., and Munger, S. D. Modulation of taste sensitivity by GLP-1 signaling in taste buds *Annals of the New York Academy of Sciences* 2009 1170:98-101
47. Ban, K., Hui, S., **Drucker, D. J.**, and Husain, M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies 2009 *Journal of the American Society of Hypertension* 2009 3(4) 245-259
48. **Drucker, D. J.**, Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., and Buse, J. B. Incretin-based therapies for the treatment of type 2 diabetes; evaluation of the risks and benefits *Diabetes Care* 2010 33:428-433
49. **Drucker, D. J.**, Dritselis, A., Kitkpatrick, P. Liraglutide *Nature Reviews Drug Discovery* 2010 Apr;9(4):267-8.
50. **Drucker, D. J.** & Goldfine, A. B. Cardiovascular safety and diabetes drug development *Lancet* 2011 377(9770):977-9.
51. **Drucker, D. J.**, Sherman, S. I., Bergenstal, R. M., and Buse, J. B. The safety of incretin-based therapies; review of the scientific evidence *J Clin Endocrinol Metab* 2011 96(7); 2027-2031
52. **Drucker, D. J.** Incretin-based therapy and the quest for sustained improvements in beta cell health *Diabetes Care* 2011 34(9): 2133-35
53. **Drucker, D. J.**, and Rosen, C. F. GLP-1 receptor agonists, obesity and psoriasis: diabetes meets dermatology *Diabetologia* 54:2741-2744
54. **Drucker, D. J.** Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders *CMAJ* 2012 Feb 7;184(2):E153-4
55. Ussher, J. R., and **Drucker, D. J.** Cardiovascular biology of the incretin system *Endocrine Reviews* 2012 Apr;33(2):187-215
56. Campbell, J. E., **Drucker, D. J.** Pharmacology, physiology, and mechanisms of incretin hormone action *Cell Metabolism* 2013 Jun 4;17(6):819-37.

57. Sadry, S., **Drucker D. J.**, Emerging combinatorial hormone therapies for the treatment of obesity and T2DM 2013 9, 425-433
58. **Drucker, D. J.** Incretin action in the pancreas; potential promise, possible perils, and pathological pitfalls Diabetes. 2013 10: 3316-3323
59. Lovshin, J. L., and **Drucker D. J.** Metabolic Disease Puts Up a Fight: Are diet and exercise helpful for the heart? Nature Medicine 2013;19:1216-1217
60. **Drucker, D. J.**, and Yusta, B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2 Annu Rev Physiol 2014;76:561-583
61. Ussher, J. R., and **Drucker D. J.** Cardiovascular actions of incretin-based therapies Circulation Research 2014 May 23;114(11):1788-1803
62. Mulvihill, E. E., & **Drucker, D. J.** Pharmacology, physiology and mechanisms of action of dipeptidyl peptidase-4 inhibitors Endocr Rev. 2014 35(6): 992–1019, 20
63. Drucker, D. J. Deciphering metabolic messages from the gut drives therapeutic innovation The 2014 Banting Lecture Diabetes 2015 Feb;64(2):317-26
64. Campbell, J. E., **Drucker, D. J.** Islet α cells and glucagon-critical regulators of energy homeostasis Nature Reviews Endocrinology 2015 Jun;11(6):329-338
65. Bouillon, R., **Drucker, D. J.**, Ferrannini, E., Grinspoon, S., Rosen, C., and Zimmet, P. The past 10 years-new hormones, new functions, new endocrine organs Nat Rev Endocrinol. 2015 Nov;11(11):681-6
66. **Drucker, D. J.** Evolving concepts and translational relevance of enteroendocrine cell biology J Clin Endocrinol Metab 2016 101(3):778-86
67. **Drucker, D. J.** The cardiovascular biology of glucagon-like peptide-1 Cell Metabolism 2016 24(1):15-30
68. **Drucker, D. J.** Never waste a good crisis: Confronting reproducibility in translational research Cell Metabolism 2016 24(3) 348–360.
69. Pujadas, G., **Drucker, D. J.** Vascular biology of glucagon receptor superfamily peptides: complexity, controversy, and clinical relevance Endocrine Reviews 2016 37: 554–583.
70. Nauck, M.A., Meier, J.J., Cavender, M.A., Abd El Aziz, M., **Drucker, D. J.** Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Circulation. 2017;136:849-870
71. **Drucker, D.J.**, Habener, J.F., Holst J. J. Discovery, characterization and clinical development of the glucagon-like peptides J Clin Invest 2017 127(12):4217–4227.
72. **Drucker, D. J.** Mechanism of Action and Therapeutic Application of glucagon-like Peptide-1 Cell Metab. 2018 Apr 3;27(4):740-756
73. Gloyn, A. L., **Drucker D. J.** Precision medicine in the management of type 2 diabetes Lancet Diabetes Endocrinol. 2018 Nov;6(11):891-900
74. **Drucker, D. J.** The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications Diabetes 2018 Sep;67(9):1710-1719

75. **Drucker, D. J.** The discovery of GLP-2 and development of teduglutide for short bowel syndrome ACS Pharmacology and Translational Science 2019, 1:2(2) 134-142
76. Müller, T.D., Finan, B., Bloom, S. R., D'Alessio, D., **Drucker, D. J.** Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., Seeley, R. J., Stemmer, K., Tang-Christensen, M., Woods, S. C., DiMarchi, R. D., Tschöp, M. H. Glucagon-like Peptide-1 (GLP-1) Mol Metabolism 2019 (30) 72-130
77. Beaudry, J. L., **Drucker D. J.** Proglucagon-Derived Peptides, GIP and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue Endocrinology 2020;161(1):bqz029. doi:10.1210/endo/bqz029
78. **Drucker D. J.** Advances in oral peptide therapeutics Nature Reviews Drug Discovery 2020 Apr;19(4):277-289
79. **Drucker D.J.** Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications Endocr Rev. 2020 June 41(3) 457-470. doi: 10.1210/endo/bnaa011
80. Baggio, L.L. & **Drucker D. J.** Glucagon-like Peptide-1 Receptor co-agonists for the treatment of metabolic disease Mol Metabolism 2020 46:101090
81. McLean, B.A., Wong, C.-K., Campbell, J. E., Hodson, D., Trapp, S., **Drucker D. J.** Revisiting the complexity of GLP-1 action-from sites of synthesis to receptor activation Endocrine Reviews 2021 Mar 15;42(2):101-132
82. **Drucker, D. J.** Diabetes, obesity, metabolism and SARS-CoV-2 infection. The end of the beginning Cell Metabolism 2021 Mar 2;33(3):479-498
83. **Drucker D. J.** Transforming type 1 diabetes: the next wave of innovation Diabetologia 2021 May;64(5):1059-1065
84. **Drucker, D. J.** GLP-1 physiology informs the pharmacotherapy of obesity Mol Metabolism 2021 Oct 6:101351. doi: 10.1016/j.molmet.2021.101351
85. Cherney, D. C., Udell, J., **Drucker D. J.** Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors MED 2021 2 (11), 1203-1230
86. Yabut, J., & **Drucker D.J.** Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease Endocrine Reviews 2022 Jul 30:bnac018. doi: 10.1210/endo/bnac018.
87. Hammoud, R., **Drucker D. J.** Beyond the pancreas — contrasting cardiometabolic actions of GIP and GLP-1 Nat Reviews Endocrinology 2022 Dec 12. doi: 10.1038/s41574-022-00783-3
88. **Drucker, D.J.** & Holst, J.J. The expanding incretin universe-from basic biology to clinical translation Diabetologia 2023 DOI 10.1007/s00125-023-05906-7
89. Ussher, J.R. & **Drucker D.J.** Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action Nat Rev Cardiol. 2023 Mar 28. doi: 10.1038/s41569-023-00849-3.
90. **Drucker, D. J.** Prevention of cardiorenal complications in people with diabetes and obesity Cell Metabolism 2024 Jan 1(36)2:358-353.. doi: 10.1016/j.cmet.2023.12.018
91. **Drucker D. J.** The GLP-1 journey:from discovery science to therapeutic impact J Clin Invest. 2024 Jan 16;134(2):e175634
92. **Drucker, D.J.** The efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity Diabetes Care 2024 Nov 1;47(11):1873-1888.<https://doi.org/10.2337/dci24-0003>

93. **Drucker D.J.** The benefits of GLP-1 drugs beyond obesity *Science*. 2024 Jul 19;385(6706):258-260. doi: 10.1126/science.adn4128
94. Abel, E.D., Gloyn, A.L., Evans-Molina C., Joseph, J.J., Misra, S., Pajvani, U., Simcox, J., Susztak, K., **Drucker, D.J.** Diabetes Mellitus – Progress and Opportunities in the Evolving Epidemic *Cell* 2024 (187) 3789-3820
<https://doi.org/10.1016/j.cell.2024.06.029>
95. **Drucker D.J.** Expanding applications of therapies based on GLP-1 *Nat Rev Endocrinol*. 2025 Feb;21(2):65-66. doi: 10.1038/s41574-024-01066-9
96. **Drucker D.J.** Discovery of GLP-1 based drugs for the treatment of obesity *N Engl J Med*. 2025 Feb 6;392(6):612-615. doi: 10.1056/NEJMcibr2409089
97. Müller T.D, Adriaenssens A, Ahrén B, Blüher M, Birkenfeld A, Campbell J.E, Coghlan MP, D'Alessio D, Deacon C.F, DelPrato S, Douros J.D, **Drucker D.J**, Figueredo Burgos N.S, Flatt P.R, Finan B, Gimeno R.E, Gribble F.M, Hayes M.R, Hölscher C, Holst J.J, Knerr P.J, Knop F.K, Kusminski C.M, Liskiewicz A, Mabilieu G, Mowery S.A, Nauck M.A, Novikoff A, Reimann F, Roberts A.G, Rosenkilde M.M, Samms R.J, Scherer P.E, Seeley R.J, Sloop K.W, Wolfrum C, Wootten D, DiMarchi R.D, Tschöp M.H. Glucose-dependent insulinotropic polypeptide (GIP) *Molecular Metabolism* 2025 Feb 28:102118. doi: 10.1016/j.molmet.2025.102118
98. Deota S, Pendergast JS, Kolthur-Seetharam U, Esser KA, Gachon F, Asher G, Dibner C, Benitah SA, Escobar C, Muoio DM, Zhang EE, Hotamışligil GS, Bass J, Takahashi JS, Rabinowitz JD, Lamia KA, de Cabo R, Kajimura S, Longo VD, Xu Y, Lazar MA, Verdin E, Zierath JR, Auwerx J, **Drucker DJ**, Panda S. The time is now: accounting for time-of-day effects to improve reproducibility and translation of metabolism research *Nat Metab*. 2025 Mar;7(3):454-468. doi: 10.1038/s42255-025-01237-6
99. **Drucker D.J.** GLP-1-based therapies for diabetes, obesity and beyond *Nature Reviews Drug Discovery* 2025 DOI10.1038/s41573-025-01183-8
100. Campbell, J.E., & Drucker D.J. Therapeutic Targeting of the GIP Receptor-Revisiting the Controversies *Diabetes* 2025 :db250393.doi: 10.2337/db25-0393
101. Gonzalez-Rellan, M.J, **Drucker D.J.** The expanding benefits of GLP-1 medicines *Cell Reports Medicine* 2025 Jul 15;6(7):102214. doi: 10.1016/j.xcrm.2025.102214
102. Xu Y, **Drucker DJ**, Traverso G, Belouqui A. Innovative molecules and delivery technologies enabling the future of GLP-1-based therapies *Endocrine Reviews* 2025 Aug 4:bnaf027. doi: 10.1210/endrev/bnaf027